This article isprotected rights by All copyright. reserved. 10.1111/all.13806 doi: lead todifferences version between this andthe ofPleasecite articl Version Record. this been and throughtypesetting, proofreadingwhich may thecopyediting, process, pagination This article ha 4 Republic Czech Prague, 3 2 Lund, Sweden 1 Affiliations Tufvesson Lutter Hamelmann Custovic Diamant Zuzana Authors positionpaper app clinically Towards typeArticle : EAACI Position Paper DR. SVEN (OrcidSEYS ID : 0000 PROF. IOANA AGACHE (Orcid ID : 0000 PROF. ENRICO HEFFLER (Orcid :ID 0000 DR. LIAM HEANEY PROF. ECKARD HAMELMANN (Orcid ID : 0000 DR. ROY GERTH VAN WIJK (Orcid :ID 0000 DR. SUSANNE VIJVERBERG (Orcid ID : 0000 Accepted UMC Amsterdam Medicine, Respiratory Dept. of of First Faculty Medicine, Respiratory of Dept QPS and UMCG Pharmacology, & Pharmacy Clinical of Dept & Allergology, Medicine Respiratory of Dept Article 4 ,
7 Anna Sven , 2 ,
Ioana Ioana Agache 1
2 , Liam Heaney Liam , - s been accepted for publication and undergone for and buthas accepted s been not review publication fullpeer ai Olin Carin - rk Dahlen Erik 1 ,2 ,3 (Orcid ID: 0000 ,
uan Vijverberg Susanne
21 1 8 , Seln Sergejeva Svetlana , Sven 1 8 3 Mn Gaga Mina , , Enrico Heffler Enrico , - 0002 licable F. Seys - 0003
- 4399 - 2 0001 2 Institute for Clinical Science, Skane University Hospital, Hospital, University Skane Science, Clinical for Institute 4 9 - -
,
Ry et vn Wijk van Gerth Roy , Medicine, Charles University and Thomayer Hospital, Hospital, Thomayer and University Charles Medicine, 2063 0002 jl Alving Kjell - b -
- 0002 , University of Amsterdam, , University 9892) 1 0002 - i 4,15 7994 omarkers - - - 0002 7992) 0492 , Ömer Kalayci Ömer , 1 - 9 - 9608
Agl Simpson Angela , 4579 - 364X) - - 2996 - 5663)
NL, NL, 5 - - Az Baki Arzu , 8742) 4081) Groningen, The Netherlands The Groningen,
- 8248)
for
1 6 10 ,
Seao e Giacco Del Stefano ,
Konstantinos Kostikas Konstantinos a rtas
sthma Amsterdam, The Netherlands The Amsterdam, 20 Peter , 6 ,
ef Bjermer Leif
– J.
n EAACI An Sterk
1 1 2 Eckard , Adnan , 4 1 Ellen , 7 , e as Rene
This article isprotected rights by All copyright. reserved. 3000 Leuven Herestraat 49/811 Laboratory ofClinical Immunology Dr. Sven Seys Corresponding author Transplantation 22 21 Kingdom United Manchester, Trust, Foundation NHS Manchester Un and of Manchester University Sciences Centre, Health Academic Manchester 20 1 1 1 1 1 1 Ireland Northern 1 Germany 1 1 10 9 Sweden. Stockholm, 8 7 Turkey Ankara, 6 5 1 Greece Athens, Hospital, Chest Athens Centre, Asthma and Department Medicine 7th Respiratory Resea and Allergy Asthma Experimental Kingdom United London, London, College Imperial Medicine, of Department Paediatrics, Section of of Medicine, School University Gazi Asthma, and Allergy Pediatric of Division Pediatrics, of Department Sweden Uppsala, University, Uppsala Health, Children's and Women's of Department 9 8 7 6 5 4 3 2 Accepted Group, Research Immunology Clinical and Allergy Romania Brasov, University, Transylvania of Medicine, Faculty Immunology, Clinical and Allergy of Dept Health, and Medicine of Biology, Faculty Medicine, Respiratory and Immunity of DivisionInfection, Estonia Tartu, Tartu, of University Technology, of Institute Universi Academy, Sahlgrenska Medicine, Environmental and Occupational Section of Department Medicine Respiratory Division and Allergy Asthma Medicine, Personalized Article Sciences of Biomedical Department R Regional Hospital, City Belfast Bochum, University Ruhr Center, and Allergy Bielefeld; Bethel, Hospital Protestant Children’s Center, Italy of Cagliari, University Health, Public and Sciences of Medical Department Center, Medical Erasmus Medicine, Internal dept. Allergology, Section of
of Pediatric Allergy, Faculty of Medicine, Hacettepe University, Ankara, Turkey Ankara, University, ofHacettepe Medicine, Faculty Allergy, Pediatric of
, KU Leuven, Leuven, Belgium KU Leuven, ,
espiratory Centre, Belfast, United Kingdom of Great Britain and Britain and Great of Kingdom United Belfast, espiratory Centre, , University of Ioannina Medical School, Ioannina, Greece Ioannina, School, Medical Ioannina of University -
Humanitas University University Humanitas rch, Institute of Environmental Medicine, Karolinska Institutet, Institutet, Karolinska Medicine, Environmental of rch, Institute -
Humanitas Research Hospital Hospital Research Humanitas Department of Department
–
Milan, Italy Milan,
Microbiology Rotterdam, the Netherlands the Rotterdam,
–
Milan, Italy Milan, iversity Hospital of South Hospital iversity
, Immunology
ty of Gothenburg
and and
This article isprotected rights by All copyright. reserved. dis heterogeneous highly a with therapy asthma, of spectrum (AHR) physiological hallmark The Introduction asthma monitoring existing different Immunology Clinical validated been have biomarkers patie identify single or pathways inflammatory specific treatment into integrated increasingly During type surprisingly also in non type increased heterogeneous a I Abstract Key words E: [email protected] 0032 T: 16342667 Belgium nflammation Accepted Articlesthma.
2 inflammatio 2
,
asthma is the best the is asthma thepast and structural and as well as
inflammatory biomarkers inflammatory
lhuh t Although
biomarker levels of eosi of levels : precision medicine, phenotype, endotype, eosinophil, FeNO, IgE of severe asthma inhaled corticosteroidsinhaled ,
t wo il eei fo the from benefit will who nts signs s structural
decade pcrm of spectrum f sha nld crnc iwy inflammation, airway chronic include asthma of
applicable biomarkers.
n lessis clear.
ee rcse ae well are processes hese
nldn vral ara osrcin and obstruction airway variable including apig ehd ad to and methods sampling (EAACI) changes contribut , - nophils targetedtherapies, including a - llergic n functional and defined endotype, defined
.
Subsequently sha T asthma. order
, ak oc o Boakr in Biomarkers on Force Task within the within
FeNO patients with ing
o ciia application clinical for
(point
to
(ICS)
ossig of consisting and type and
h v the ype strategies - abnormalities of
lower (3) , we mediators -
typically care) - ifamtr response inflammatory 2 ral rsos to response ariable se (severe) . documented
E
discuss 2
specially severe specially airways treatments
cytokines investigate
to of support biologic foun multiple . asthma severe severe b composite or Single existing and within .
(1,2) d h Erpa Aaey f leg & Allergy of Academy European The ter expression their ,
in patients with with patients in in blood and/or airways. Presently, airways. and/or blood in .
al o far, So diagnosis, clinical . asthma.
. A s T
h aras r ky etrs of features key are airways the overlapping These f These tm ws ntae to initiated was sthma he etiology of and small molecules, asthma iwy hyperrespons airway tnad anti standard novel
only plcblt of applicability eatures hs treatments These lncl s clinical s targeted has been has
are targeted therapies a
allergic
phenotypes few to help iomarkers ais cos the across varies asthma hrceie by characterized differ y - treatment and treatment
recog inflammatory inflammatory pos and mptoms asthma, butasthma,
across the across
havebeen with e and new nized iveness review with ,
block non for as -
This article isprotected rights by All copyright. reserved. (cost D ‘Economical’ outcomes), patient (improve ‘Valuable’ management), patient (change ‘Actionable’ practice), current (outperform ‘Superior’ to applicable clinic reach to potential high a with biomarkers 1) progression todisease applicable biomarker a as qualify to order In What is a clinically applicable biomarker? asthma In inflammation, and W impact. evaluatio and validation biomarker requires and challenging however a well and ( asthma (severe) (SARP). Program Respiratory Asthma PREDictionin BIOmarkersrespiratoryoutcomesdisease (UBIOPRED)of consortium Novel targeted hold asthma d decade, past the In patients asthma their control a to responsiveness differen pproximately 5 pproximately eployable’ e review .
Acceptedpart second the Article T biomarkers for the diagnosis, monitoring and treatment of asthma of treatment and monitoring diagnosis, the for biomarkers s biologic he he
s monitor the monitor s promise to improve asthma management and guidance into selecting the most adequate most the selecting into guidance and management asthma improve to promise approaches to unravel to approaches
in context with e in ces phenotypes
(7) treatment for each individual patient so ed - . ald ‘’ called (analysis technology available in clinical laboratory) al
the
validat while
markers that can guide the choice of treatment, of choice the guide can that markers age of onset, onset, of age -
literature 10% of patients of 10% e.g., of this paper this of ICS
treatment SAVED of (8 non e istinct or targeting IgE, targeting
–
chronic airway diseases, airway chronic clinically applicable biomarkers asthma and 10) have - type 2 inflammation and structural abnormalities structural and inflammation 2 type ’’ . between 1990 and 2018
molecular The identification of identification The natural model model corticosteroid biologic
response. imres Acrig o hs oe, boakr hud be should biomarker a model, this to According biomarkers. , we discuss existing and existing discuss we , lncl rsnain comorbidities, presentation, clinical either
IL course a proposed was al 5, ih h avn o nvl expensive novel of advent the With mechanisms
asthma networks are emerging, are networks asthma IL Implementing need 4/
f disease of
insensitiv IL
(11 high doses of doses high 13 validation at different levels is required (Figurerequired is levels different at validation –
inflammatory subsets and subsets inflammatory l translation al and others), there is a strong need of clinical of need strong a is there others), and 13)
- vlae treatment evaluate on have been have aig r cost or saving o ecie h caatrsis f COPD of characteristics the describe to . ity
non
and address unmet needs targeted (4
and novel
– - 6)
or semi ICS , .
hence
codn t literature, to According
identified
targeted therapies for (severe) for therapies targeted
predict treatment response, treatment predict treatment into treatment (15) (14) and/ - inv - , . Ti model This .
‘Clinical and effective) classify as severe asthma severe as classify or n of the socio the of n
asive , with a focus on focus a with , epne n monitor and response oral corticosteroids oral airway
such as such and
biologic are also discussed also are asthma end asthma sampling methods
linked to linked daily .
inflammation, the Unbiased the may may
al and Severeand
- practice is practice economic t treat to s also also clinical overall otypes type 2 type
be as to ly .
This article isprotected rights by All copyright. reserved. complex capture can that issue crucial The phenotyping. or diagnosisprobabilistic for suitable are eNoses) and VOCs of mixtures noses: (electronic algorithms recognition pattern with (GC spectrometry approaches: and signal molecular comprehensive more a providing are atopy status, smoking the condens as (such samplings ( been have methods existing During far fluctuations daily significant even is eosinophilia tissue some obtain tract respiratory the outside facilities laboratory equipped N invasive these procedures preclude ( lavage bronchoalveolar tree bronchial the of sites different tissue ad In primarily brushes nasal and brushes bronchial biopsies, U from studies comparative underlying question the biomarkers Inflammatory B including iomarker sampling methods Accepted evertheless Article not upper and lower and upper interpretation dition, e dition,
- - ed and ed
been n tu peual ms disease most presumably thus and u nt n all in not but h ls decades last the
a
allowing te (EBC) s whether is be considered as
fraction mechanisms
established ,
ach ach
i.e. blood eosinophils have been shown to correlate to shown been eosinophilshave blood it
i s a sampling
repeated and repeated - (27
time ayia ceity ehius sc a gs chromatography gas as such techniques, chemistry nalytical MS) al f FeNO of volatile organic compounds [VOCs]) in exhaled breath exhaled in [VOCs]) compounds organic volatile
respiratory tract respiratory – xae nti oie [FeNO] oxide nitric exhaled all – and 29) -
to consuming and consuming .
stu
of , BAL hs cmatet ae rvdn cmaal ifrain n the on information comparable providing are compartments these
.
of
dniy niiul Os r cross or VOCs individual identify several bronchoscopy a anti (severe) asthma. (severe) method has its own advantages and limitations (Table 1). (Table limitations and advantages own its has method Despite dies
representative ofaparticular sampl - (26) asthma can be sampled in different different in sampled be can asthma is ) IPE o gn epeso profiles expression gene on BIOPRED es clear less
refined refined
fluid - implies often inflammatory reproducible (21
n personnel and , while , n the . However, the invasiveness and potential complication potential and invasiveness the However, . is bronchoscopy is – ovel
24) hampered ,
both simple technology and co saliva, requires
oeta dabcs P drawbacks. potential . an ,
(25)
in daily clinical routines h creain ewe bod oiohl ad lung and eosinophils blood between correlation The non - unambiguous pcfc ehd o ses iwy inflammation airway assess to method specific T o online for . samplings his treatment - urine naie ehd hv be developed been have methods invasive n addition In
specialized by ( may not be the case the be not may 19,20) ) (16,17)
and peripheral blood peripheral and combining several and (real of . (esp
offline offline clinically relevant clinically
Teeoe ay imre should biomarker any Therefore, . Alternatively, ( ,
can be analysed using two different two using analysed be can more
( lo esnpis r sbet to subject are eosinophils blood - - perturbing ecially medical ecie esr arrays sensor reactive time) with
bronchial rpea blood eripheral ing mmercial ) body dlyd analysis) (delayed
(18) central airway inflammation. airway central sputum
site. corticosteroids) assess ) in
. Sputum induction less is as shown for instance by instance for shown as compartments infrastructure
ptm endobronchial sputum, factors apig biomarkers sampling ly
biops (11,16 et of ment
eosinophil
and exhaled breath exhaled and availabl cut - ies , off – including a be can , brushes , 18)
valu e bio ih mass with
(30)
biomarker , with well with analyzers
combined .
The most The including counts The first The markers e ,
. VOCs . has eas while
age, s and
il so in of at y s - ,
This article isprotected rights by All copyright. reserved. may it far. so biomarker ( Multiple pathophysiological event (TSLP) levels FeNO low of number higher significantly FeNO levels (>25ppb) and low blood eosinophils (<2%) described. was eosinophilia phenotype (39,41) with e helper2) by characterized (39,40) t The Biomarkers of 2 type biomarkers (MRI) techniques, microbiomics) epigenetics, from obtained biomarkers collection concentrations for methodology standardized vapor b Additionally, identify to potential a external independentincluding analysis, for allergic osinophilic airwayinfiltrationosinophilic
Accepted Articlenovel both VOCs techniques VOCs both ype 2 ype T2 , as well as non as well as , , and positron emission tomography emission positron and ,
,
. non , also )
gene inflammatory
IL T2 airway and asthma ,
25, (T2) ’’
including
reflect sal ascae with associated usually - but willnot be further discusse microbiomics) and have sha s rsnl te best the presently is asthma
invasive nae mil int lmhi cls ye (ILC2)) 2 type cells lymphoid innate (mainly innate iomarkers in iomarkers expression
IL are often
inflammatory pattern inflammatory
inflammation increased (45) While in general, e general, in While
33 (43) been
or deec t ICS to adherence poor , currently
applicable clinically - .
ne dtcin limits detection under . tomography computed quantitative volatile with Sputum e Sputum (T2) components sampling
Epithelial proposed
(44)
consist of consist oprd o a to compared saliva (for g (for saliva
release of release exhaled air exhaled inflammation subsequent .
molecules
en explored being (Figure 2) (Figure equaling sensitizations against aero against sensitizations osinophils ,
ehd of method -
eie cytokines, derived a Fgr 3) (Figure
nd have beenhave evaluatedfor osinophilia
rigorous standardization of sampling, of standardization rigorous IL enetics is
aa or nasal can also be also can 4,
allergy
. However, this approach is limited due to the lack of lack the to due limited is approach this However, . data the defined .
IL
activation biomarkers
Approximately
(PET) are
eeec population. reference
d in this overview 5 and/or 5
-
(47) the
characterized rprin f ains ih eosinophilic with patients of proportion
(42) validation (29) and cytokines and s el as well as
, probably the best probablythe
suggests and validated validated and , iig li fo sal airways small from fluid lining .
although by rnha sponges bronchial are increasingly applied increasingly are . . oprd o gui to Compared
obtained eety a ugop f ains with patients of subgroup a Recently,
Furthermore
increased IL of including with 13
(31) cortico L2 may ILC2 50%
allergens compar allergens
likely (qCT)
non their endotype ), nasal swabs nasal ), h Px mto i still is method PExA the variab from .
Particles in exhaled air (PExA), is (PExA), air exhaled in Particles (36)
T2 of
- steroid responsivenesssteroid hmc toa lymphopoietin stromal thymic allergic (34,3 -
mgei rsnne imaging resonance magnetic , , from both adaptive (mainly T (mainly adaptive both from characterized andcharacterized potential asthma patientsasthma cytokine EBC . methods sampling new
T2 e imre lvl with levels biomarker le
deline
immune cells cells immune (for
5)
support , These patientsshowed a within iwy nlmain is inflammation airway con . And finally, finally, And . pathway
- to and transcriptomics (for transcript (for as a biomarkera as sis ae management based (37,38) e pre d to patients with patients to d evaluate
ting of ting h eosinophilic the - h underlying the processing
are identifiedare s
(32,33)
or epithelial or eutn in resulting most condensed of ‘’ evolving
imaging imaging (39,46) asthma airway omics useful
The .
of
high and and
T2 - , , , .
This article isprotected rights by All copyright. reserved. BAL in eosinophils profiles VOCs VOCs Exhaled children severewith asthma or adults in therapy guide to FeNO of use the recommend not do guidelines asthma in reduction not FeNO incorporating ppb <25 FeNO for unlikely is inflammation ( smoking (58,59) F eligible patients for of Profiling classification T2 beyond asthma with patients amongst heterogeneity showing analysis, pathways inflammatory o reports earlier confirm IL 5 into classified be could classificatio priori (20) endotypesT2 analysis mRNA Sputum sputum has been described novel a Recently, predictor especially eosinophilia, ora on patients in especially (50) C sputum by guided treatment severe more with patients eo sputum adults eNO eNO oncomitant systemic and systemic oncomitant Accepted 5 Article -
in children) in high expression was restricted to patients with an with patients to restricted was expression high . A recent unsupervised sputum analysis of an mRNA panel of 12 cytokinesthea12challenged of panel mRNAan recentanalysisunsupervisedsputumof A . .
However, is ) .
, and >35 ppb >35 and However, a atopy f ICS of sinoph reproducible, T2
asthma (37,38)
rvd a opst boakr inl bsd n atr rcgiin Exhaled recognition. pattern on based signal, biomarker composite a provide
r creae wt bod oiohl n nurpi counts neutrophil and eosinophil blood with correlated are
yoie patter cytokine n diet and (62)
lo ad s and blood epne ih epc t bt atm smtm ad exacerbations and symptoms asthma both to respect with response
il n of T2 versus non versus T2 of n point - (65)
FeNO biologic (7) guided in . In a study in pregnancy, FeNO pregnancy, in study a In . . Inhal xcrain and exacerbations to standard clinical practice clinical standard to ( .
children . in combination in - is a more sophisti more a is Even n of (37,55)
aiy measur easily (29,60,61)
clusters with equal proportions of proportions equal with clusters a be may
a subgroup of patients with patients of subgroup a - airway ed al care which can management asthma s targetings different corticosteroids l
without allergen uu eosinophils putum )
n Rcnl, this Recently, . analysis
ehd o rpd uniiain f oiohl eoiae in peroxidase eosinophil of quantification rapid for method s is indicative of indicative is
eosinophilia fetd by affected y eo cl mlilx technology multiplex Scale Meso by
. (48) -
A T2
identify information on an on information resulted in crig o h AS eomnain, eO 5 ppb >50 FeNO recommendations, ATS the to ccording with allerg with able
ERS/ATS . asthma mean mean hwd a showed for c ated technique t technique ated
biomarker
eee sha in asthma severe patients with
(
adults ha (24,51,52) eea confounders, several C dose ICS was
(10) eosinophilic inflammation eosinophilic T
s upregulation pathwayof T2 in sputum mRNA ic allowed
2 pathways been ant las e sd interchangeably used be always cannot
sensitization, was found to be a significant a be to found was sensitization, - n rcn GINA recent and reinforced reduction guided ) .
A set of 205 unselected asthma patients asthma unselected 205 of set A concomitant activation of Th2 and Th17 and Th2 of activation concomitant IL n <20ppb and n a and
associated with worse asthma control asthma worse with associated 25 individual (63) .
reduc n children In o cla o - airway , treatment IL IL .
(54) od rdco of predictor good
Presently 17A/F 4 in y cmlt transcriptomics complete a by ssify patients into T2 and non and T2 into patients ssify tion in tion - , experienced centers centers experienced xcrain, seily in especially exacerbations, IL . eosinophilia ’s
(
13 molecular pathways molecular children - includi high pattern. These data These pattern. high
, guidelines
resulted in resulted - ICS doses i doses ICS high patients, whereas patients, high blood of presence the
,
a hl t identify to help may t e R/T severe ERS/ATS he , while eosinophilic while ng )
(58) (54) (64) demographics,
ICS now
n adults (butadults n a significant a . .
Strategies and response suggest (7,49)
,
(53) such with (9) - . . , .
This article isprotected rights by All copyright. reserved. independent cohorts of presence recent A one. than useful more eosinophilia sputum of identification for accuracy and eosinophils, blood FeNO, review, systematic from Apart Urin leukotrienes of marker end the (LTE4), E4 leukotriene Urinary to responses to response peptidase Dipeptidyl are higher in children, probably due to growth potentialsinceasbiomarkerbaselinechildren, periostin levels in periostinused can bewhether more a obtain to required is sampling possibly complicating not However, IL periostin in confirmed not was IgE serum and eosinophils showed of marker surrogate a as proposed was Periostin production by epithelial cells was validation children in available is cortico sensitive VOCs, exhaled of principle classification. phenotypic in powerful very be can approach probabilistic 13
Acceptedconfirm Article in periostinin ary oolnl nioy (mAb) antibody monoclonal steroids
LTE4 superior
ifrn thresholds different showed . lebrikizumab
than
to tralokinumab to the potential role ofDPP
CysLT ige biomarkers single
an 3% sputum eosinophils in 60% of patients of 60% in eosinophils sputum 3% (74) could t dtcin y various by detection its
- (67) t highpatients eO r ptm oiohla n rdcig lncl fiay f systemic of efficacy clinical predicting in eosinophilia sputum or FeNO i -
IL
predict improve ciiy n hs en tde in studied been has and activity and in aspirin aspirin in and
be apotential biomarker in studies involving eicosanoid pathways . 13
, FeNO, blood eosinophils and the activation status ofb - However, 4 (DPP 4
efficacy treatment (28) follow ion et in ments in 59 patien 59 in in lung function and health status health and function lung in NS can eNOSE . -
4) has been proposed as a candidate predictive biomarker for the for biomarker predictive candidate a as proposed been has 4) T (71) f ptm and sputum of - o tee isoforms these for herefore p studies up cmoie akr hv be apid n oe studies. some in applied been have markers composite , most studies most
could study showed that this approach could accurately identify the identify accurately could approach this that showed study . .
It shouldnotedbethat severa It - , in contrast contrast in , P r NSAIDs or
4 as ug ucin fe treatment after function lung tet wt DPP with atients
not consis , ts with ts T
predict loss of asthma control control asthma of loss predict
a surrogate application of application 2 home
be - eaoie f ytiy leukotriene cysteinyl of metabolite (21,23,69) inflammation shown tent p tent confirmedsubsequenttwo in are small and focused on adults on focused and small are bronchial - (72) - xcrae rsiaoy disease respiratory exacerbated uncontrolled ae r omrily vial assays available commercially or made . to
eriostin signal in asthma. Finally, asthma. in signal eriostin to be induced by . Furthermore
(24)
T2 serum ains ih o periostin low with patients . - sha nevnin tde with studies intervention asthma sha p Asthma
eNose in daily practice daily in eNose lvl aoe median above levels 4 biomarker. Cmiig l tre akr my be may markers three all Combining . . ise oiohla hn eO blood FeNO, than eosinophilia tissue In (77)
t
g soe mdrt diagnostic moderate showed IgE severe asthma severe he BOBCAT he .
(73) Using a prediction model in two in model prediction a Using , l tet wt increased with atients t s nnw wehr local whether unknown is it periostin
. Further studies are needed are studies Further . IL with 13 (66)
(39) study erkzmb a anti an lebrikizumab, phase lood eosinophils and splicevariantsexist, B (68)
, while while , . Asp such, and sd n h same the on ased
, serum periostin serum , (CysLT s requires further requires . show
3 However, may may (NERD) studies levels it is unclear is it scarce
ed (76) e more be eriostin s
) serum better
, i a is ,
. (75) (70) even anti with
data n a In this - - . .
This article isprotected rights by All copyright. reserved. Accepted for receptor neutrophil sputum with correlated positively neutrophils, 3 type or cells T by produced Several asthma (93) phenotype asthma severe most the Study is asthma Asthma Childhood of Consortium Tawainese relation expression asthma, resistant treatment increased not were numbers numbers in study a (88) neutrophilia refractory have to shown were asthma refractory to insensitivity Articlereported lacking still is inflammation paucigranulocytic range The Biomarkers of established profiles biomarker composite of role treat evaluated respectively) cohort, validation the in cohort training in specificity 91.5% and sensitivity (90.5% predictaccurately characteristics could clinical with combined neutrophils
. . non
In childhood asthma,childhoodn In n h inner the In
eg T2 (e.g. (56) ship - cytokines
T2 of eosinophils in BAL, endobronchial biopsies and sputum samples sputum and biopsies endobronchial BAL, in eosinophils of (41,50,83,84)
. ains ih asthma with patients were
hlrn ih eee asth severe with children
. endotype consists of patients of consists endotype
between airway neutrophilia and asthma severity in children. The children. in severity asthma and neutrophilia airway between often by IL
, was 8, ment non ICS - tutrl cells structural low) associated with better lungfunctionbetter associated with - airway inflammatory pattern inflammatory airway iy study city associates with (subclinical) airw (subclinical) with associates
soit wt suu neutrophil sputum with associate - (41)
type 2 inflammation response in patients in response .
on t be to found hs endotype This . i smoking in , Sputum eutrophilic airway eutrophilic since the presence of intra of presence the ,
Th
(91) (44,94,95) ILCs 17
various sputum neutrophil cut off levels off cut neutrophil sputum various neutrophil (88) nrae n etohlccmae t oiohlc asthma eosinophilic to compared neutrophilic in increased - . related ,
C (85) ma, promotes onversely, n asth in . (78) covers A ihr ees f A nurpis oprd o non to compared neutrophils BAL of levels higher in whom in based on based
at rm elcig dsic peoye airway phenotype, distinct a reflecting from part
therapy Bt s Both . and in obese obese in and yoie wr ascae with associated were cytokines . ia oe lncl ras plig agtd therapies targeted applying trials clinical Some
a phenotyping ma inflammation seems to play a play to inflammationseems in children in
a fud o be to found was (82) count h pouto of production the oh ains ih neutrophilic a with patients both - in epithelial neutrophil epithelial - putum T2 resistan composite ay infection ay .
recent a (92)
A clear clear A s inflammation ia
hwd ht neutroph that showed (46)
sha patients asthma (Figure .
;
IL with with
Recent dataRecent ce 77% sensitivity and 71% specificity 71% and sensitivity 77% 17A .
- definition of neutrophilic airway neutrophilic of definition
ee expression Gene was biomarker profiles biomarker
study a
n mngmn nes o be to needs management and (89)
and poor corticosteroid response corticosteroid poor 2)
hrceie b increased by characterized
associated with with associated IL . is absent or within normal within or absent is
or nelui 17A Interleukin IL chem 8, severe with children in
s howeverdo
8 oral corticosteroid use corticosteroid oral and increase and
ee expression gene (86,87) (40 s putum eosinophiliaputum minor d
ifficult - while neutrophil while 76%) o
il analysis of the of analysis - of - trcat for attractant
. (79 predominant
role A supportthe CXCR2 - dults have been have to – d (relative) , 81)
- IL (90) c mainly and ontrol 17RA . the , with
The are .
I n a -
This article isprotected rights by All copyright. reserved. bronchoscopy detachment angiogenesis and hyperplasia glandular and membrane including a is remodeling Airway Biomarkers of structural airway abnormalities muscle, nerves and/or vessels may be theunderlying pathophysiological substrate. ‘’low uncontrolled remains these neutrophil and eosinophil sputum paucigranulocytic are asthma paucigranulocytic underlying mechanisms The hydrogen peroxide (H surrogate neutrophil sputum increased (103) of presence the specificity and sensitivity high with c c serum in biomolecules severe and TNF soluble pg/mlindependentfactorsevereasthmariskare20 abovean values for asthma. F between f mild to compared refractory in increased Similarly to increased sputum neutrophils, was (96) lrtci (108A) a agr oeue eesd by released molecule danger a (S100A8/A9), alprotectin Accepted Article investigate have studies ew . found to be - grade’’ inflammation grade’’ More . patients is well is patients hl bod etohl ae or niaos f iwy etohla s neutrophilia, airway of indicators poor are neutrophils blood While sha patients asthma Serum
ree TNF nrae dpsto o etaellr arx rtis n h rtclr basement reticular the in proteins matrix extracellular of deposition increased
biomarker (RBM) recent was was
(108) IL associated neutrophilicwith asthma IL 17 ly, the inflammasome pathway with increased expression increased with pathway inflammasome the ly, , increased airway smooth muscle (ASM) mass (ASM) smoothmuscleairway increased , also also and phenotype 8 levels 8 . was found to be to found was - s 2 controlled
sputum O ept nra suu gauoye counts granulocyte sputum normal despite lie t occur to claimed nother ae en validated been have 2
) may be amarker ofneutrophilic oxidative burst oprd o health to compared orrelat accompanied by raisedneutrophilscirculatingbyaccompanied (77)
ersn apoiaey 40 approximately represent d neutrophils in key feature of feature key , or structural changes incl changes structural or ,
with ing h ptnil f eu boakr t ietf neutrophilic identify to biomarkers serum of potential the
counts
ih A neutrophilia BAL with mild to compared asthma severe in increased a normal lung function lung normal a n situ in membrane er
ihn oml range normal within
patients with asthma asthma o neutroph for
y
(106,107) , controls
some
(97,98) ,
- (99) compris bound
argued (102) . uding epithelial cells, airway smooth airway cells, epithelial uding wees o association no whereas , severe severe - 0 of 50% lc asthma ilic h ara eihlu, a predict can epithelium, airway the lhuh b Although .
,
TNF TNF
(88) a subgroup ( subgroup a ing the .
and/or f hs reflects this if A s
asthma structural changes changes structural on circulating monocyte .
least (83) In eet nlss show analysis recent sha patients asthma (105) sha patients asthma
. .
ocil e ronchial
(101) cell cell defined While
neetnl, exhaled Interestingly, (100) have been detected indetected been have I tee ains a patients these In . (104) approximately 15% approximately of NLRP3 and NLRP3 of number .
Increased s fr no far, o .
h mjrt of majority the
. .
an ains with Patients
ihla cell pithelial er , goblet cellgoblet ,
artefact
a found was (Figure 2) (Figure forms andforms n show and s
serum , (>61%) serum s erum ed IL
wa
1 of 5 s )
This article isprotected rights by All copyright. reserved. different of Consisting AHR. with correlated variants genetic some and ASM of programs dynamics airway and proteins ASM they compounds, mitogenic of levels the attenuate underlie can corticosteroids may Although compounds mass. mitogenic ASM enhanced of presence the and matrix extracellular the Both m precise The warrant further investigation cortico pathophysiology with to remodeling correlated patients asthma from ASM in expressed differentially controls healthy T growth factor β (TGF to known is which asthma of severity factor growth fibroblast high on thickening wall bronchial s asthma, severe with children in study chitinase/chitinase g with r asthma,severeallergicantifrom in apart study methacholine against protection function lung in improvement and parallel, In fibrosis. subepithelial this driving eosinophil and the of thickening The far, So airway obstruction reflect aspect pathophysiology and remodeling underlie child in present in manifest arefeatures these Although educe Accepteddifferencespatientsrevealedmarkedasthmafrom ASM ranscriptomeofanalyses Article
lo iety fet h cnrcieeeet f ASM of elements contractile the affect directly also
d tris were steroids alectin asthma the number of number the is
RBM
assessed parallel or - thicken 3 caim diig S hprrpy n hprlsa n sha r ls clear. less are asthma in hyperplasia and hypertrophy ASM driving echanisms severity -
depleting
hood (125) (121) . - or like proteins have also been found to affect airway remodeling airway affect to found been also have proteins like hl the While -
β), a tissueremodeling factor
ing soitd with associated RBM
AHR
reliable . In . wih per t rglt ara remodeling airway regulate to appears which ,
asthma (112) hoi ara inf airway chronic
- in some pat some in
(FGF 2
this study this treatments have been correlates well with eosinophil numbers in bronchial mucosa bronchial in numbers eosinophil with well correlates .
, other associations between associations other ,
ASM biomarkers reflect biomarkers
(91,109,110) (125) - - are i ) orltd nesl wt te FEV the with inversely correlated 2) dcd aia ara narrowing airway maximal nduced -
eouin optd tomography computed resolution mass and collagen deposition deposition collagen and mass a achieved was
, several genes ( genes several ,
not always always not ients. In a subsequent analysis subsequent a In ients. (128) inconsistent . mrvmns n iwy physiology airway in improvements (114,116) C adults eae to relate ags n xrsin f hs genes these of expression in hanges erum I fc, corticosteroids fact, In . lammation suggest , reduction in symptoms and asthma exacerbationsasthma and symptoms in reduction
withchronic -
eosinophileffects,o chitinase concordant
ing
(113,114) , hwd niioy fet o components on effects inhibitory showed eoeig Thi remodeling.
n adults in which
RPTOR, VANGL1, FAM129A VANGL1, RPTOR, aspects of aspects ing Nvrhls, aaees f airway of parameters Nevertheless, . -
ie rti YKL protein like is induced by FGF
(127) ht hs srcua cags may changes structural these that asth markers
. and may may and
(115) ma, similar changes are alreadyare changes similar ma,
airway remodeling are s are remodeling airway n te xrsino various of expression the and
my ik o transforming to link may s malizumab(anti and (111)
can of this reduction correlate reduction this vary
iwy r airway (HRCT) (118,119)
n children in fet aiu cellular various affect
1 ae been have AHR FC ai ad the and ratio /FVC depend - - 0 correlate 40
2. (122) (126)
linking , induced
mdln and emodeling (124) and . Cii and Chitin .
ing . comparedto n biopsy a In - T (117) IgE; (123) ee data hese LEPREL1
hw t shown Sputum . on
by
airway d
(120) which carce (115)
. with with oral In a In d o ) ) .
This article isprotected rights by All copyright. reserved. recently published EAACI position paper guide may that biomarkers for options treatment target despite t Novel Biomarkers for recent explored forassessment of have (CLE) endomicroscopy laser confocal and (OCT) tomography coherence light other also FCFM f lung correlat wall airway structu ( microscopy matrix fluorescence of detection for allow that techniques imaging are processing, extensive less requiring assessment one in airways the of areas large covering on depending Still variation. tissue with deal to samples multiple require are Biopsies association with bronchial wall thickening in asthma and rhinosinusitischronic inflammation biomarkers. potential by induced proteins several and asthma in context, this In thickening remodeling c airway of driver major stage early remodeling airway of Biomarkers remodeling biomarkers generated by unbiased cluster analyses (e.g. U airway that likely is it components, Accepted Articleorticosteroid unction is suggestive of structure of suggestive is unction T2 reatment maximal
nlmain ( inflammation (131) (129) the gold standard to assess to standard gold the
s n itretos agtn IL13 targeting interventions and t has been shown to shown been has he T he
. management . option
standard Althoughcontroversial,c Hence ing 2 - O cytokine
ne of these, these, of ne s have been developed for patients who fail to achieve asthma control asthma achieve to fail who patients for developed been have s eee notold sha n apial o ptnily available potentially or applicable and asthma uncontrolled severe - , with histological analysis. The link between elastic between link The analysis. histological with
some inflammatory markers may be indicative of airway remodeling. airway of indicative be may markers inflammatory some iue ad 3 and 2 Figure n laser and
FCFM) airway airway remodel these treatment
of severe asthma IL
treatments. 13 has been identified as a major driver o driver major a as identified been has 13
(134) could reduce periostin, - based
GN se 5) step (GINA
- FF vsaie seiial elastic specifically visualizes FCFM . (114,115) function relationship, but relationship, function identify (137)
remodeling but remodeling goblet cell numbers in asthma in numbers cell goblet . n th In ). ing hronica high For a For has been extensively been has (135) . IL
3 c 13 - individuals at risk of developing asthma developing of risk at individuals
resolution e . l , irway inflammation has been considered theirwayconsidered beeninflammationhas lergen immunotherapy( lergen
. a b eautd y obnn multiple combining by evaluated be can Indeed
while following
an (136)
be
- depend on invasive technolog invasive on depend
BIOPRED) , Te aoiy f hs treatments these of majority The . eet tde as udri its underpin also studies recent
quantified anti mgn tcnqe lk optical like techniques imaging section - e sc a fbrd confocal fibered as such res nlmaoy hrp with therapy inflammatory applied applied requires validation requires (9) s
,
n lo ad ev as serve and blood in .
(130) e ics te latest the discuss we in the context of T2 of context the in f airway remodeling airway f AIT fibre rnhsoy but bronchoscopy fibres , and , (132,133) )
we refer to theto refer we
patterns and patterns airway wall airway
with . Besides . ly ies and ies . n the in
at an at been -
This article isprotected rights by All copyright. reserved. triamcinolone mg 80 of s dose single a to responded who asthma severe with thos than omalizumab to better child in Onlyf had 30% reduction in exacerbations eosinophil low with patients baseline FeNO the to compared FeNO the in omalizumab biomarker and high treat showed from Data treatment omalizumab to respondingnot patients identify can serum in IgE free of measurements routine asthma allergic in omalizumab to response monitoring in useful rather levelsspecificIgE are lacking total baseline and response treatment between correlations Consistent reduce systemic corticosteroids needs further investigation allergic severe to moderate with age of hospitalisations add as omalizumab cells decreasing (138) the is Omalizumab IgE TYPE 2 TARGETED TREATMENT Acceptedubstantial Article target ment outcomes ment ( . This recombinant humanized recombinant This . ew studies have investigatedlaboratory haveandstudies predictorsew the clinical ofomalizumab mast cells, basophils, eosinophils and dendritic cells dendritic and eosinophils basophils, cells, mast
arbitrary hood
that blood eosinophil blood that blood ed (146)
the cell fall inFeNO
asthma. therapies - eosinophil EXTRA Study EXTRA bound IgE and the expression of high of expression the and IgE bound .
and
(146)
is T2 first - dosesof (148) low The - - . , low n hrp t ICS to therapy on
responded significantly better to omalizumab treatment h ue f CD of use The s sub P - .
high (≥260 ROSE group (<19.5 ppb) (<19.5 group In this retrospective analysis,retrospective this In
targeting
groups ICS s (144,145) involving s
, FeNO and serum periostin serum and FeNO , (<260
e with milder with e group (≥19.5 ppb) showed showed ppb) (≥19.5 group
while study study cells
versus based on median biomarker values biomarker median on based
mAb
/μl) showed/μl) reduction 32% exacerbation in cells biologic
improv - showed asthma . 5 ptet wt ucnrle eee legc asthma, allergic severe uncontrolled with patients 850 es bspi atvto trsod hs rvn o be to proven has threshold) activation (basophil sens
S erum
/μl)
possesses 3% in the periostin
:
ing al
asthma while ;
53% 53%
(140 IgE ucsfly eue atm exacerbations asthma reduces successfully that children with more s more with children that
ht a approved was that
quality of lifeadultsquality in ofand>12 children is used to used is – versus
- 142) several activities several
affinity receptors (FcRI) on inflammatory on (FcRI) receptors affinity ains ih periostin with patients forms patients were dividewere patients .
16% ) can omalizumabWhether may potentially may (1
(139)
(149) dose omalizumab more 43) - low group. ,
respectively.with Patients high ( .
144, . . In a smaller study, children study, smaller a In .
Clinical studies show studies Clinical reduction for : 146)
binding free serum IgE, serum free binding
eee legc asthma allergic severe . Patients treated with treated Patients . e serum
vere asthma respondasthma vere
predict omalizumab predict .
On the other hand, other the On
- d into biomarker into d high n exacerbations in
but thecutbut
(150) g o antigen or IgE s eutn in resulting
versus (≥50ng/ml) effectively .
efficacy ed
9% in - years off is
that
a - ,
This article isprotected rights by All copyright. reserved. for this purpose human form (mutant both affects Both IL cut used been have or sputum, in (154) t show patients) 6000 total (in studies 13 assessed review systematic recent A effects of eosinophil depletion remain unclear. a the in even lungfunctionand control, glucocorticoid in increase modest improve cells/ asthma eosinophilic refractory appropria scores allergen rather anti of studies clinical first The been recently eosinophils b and m comprise treatments registered the with interfering Inter IL herapy enralizumab Accepted4/ Article 5 target -
offs IL ekn 5 leukin IL rvnig t bnig to binding its preventing . Patients are more likely to respond to anti to respond to likely more are Patients 13 target disappointing L 4 and (155,156) )
- ) approximatelyhal d
nue lt atmtc response, asthmatic late induced that can more accurately predict treatment outcomes.
e agt ouain ad npit wr slce for selected were endpoints and populations target te (151,152,157 ed quality of life of quality
(153) IL bsence of increased baseline eosinophil levels eosinophil baseline increased of bsence
IL
therapies
, registered in several countries 4 and 4 ( 13 bind oftypeto the α chain 2 ietd gis the against directed IL 500 cells/ 500 . Nevertheless, more research is needed to identify biomarkers identify to needed is research more Nevertheless, .
(161,162) ed Atr nta dut about doubts initial After . 5) . In
therapies
IL aeie FEV baseline IL . s nte poiig T promising another is several asthma several In these In IL 5 pathway 5 13 –
4) and 160)
downstream . ves and dupilumab ( dupilumab and L
blood eosinophils blood produced produced ,
studies the (dual blocka - anti IL available available 5 in 5 1 ( number
ptm oiohl >% r lo eosinophilia blood or >3% eosinophils sputum - plzmb n reslizumab and epolizumab IL a noted was IL
5 trials ,
5 ‘’ IL blocking - un signaling eetr ( receptors a rcpo α ( α receptor 5 treatment - sparingobservedbeeneffects have glucocorticoid ph
, of exacerbations in exacerbationsof for
asthma benralizumab show benralizumab d fully enotyped
(154) e) target 2
uncontrolled the
IL (158)
IL (21,22,158) . Various asthma treatments, such as as such treatments, asthma Various . 4 receptors ( 4 human - 5
IL - . importance symptom had significant IL
5 treatment if they have >3% of eosinophilsof >3% have they if treatment 5 Smlr fet o eaebtos asthma exacerbations, on effects Similar . 5R) ’’ C .
mild allergic mild no - IL sparing effect sparing mAb urrently, 5Rα),
effect on clinical outcomes, clinical on effect (151,152)
, although lower although , severe (159 , ug function lung s,
IL ly to uncontrolled
f eosinophils of , ed 4Rα). Therefore
– IL decrease mAb induces 161)
clinical effectiveness clinical subsequent 4Rα) have been investigated been have 4Rα) eosinophilic t ee are here and .
pcfcly target specifically . .
nte anti Another In However,
moderate asthma moderate
d rpd elto of depletion rapid a some studies some
eosinophilic asthmaeosinophilic xcrain rates, exacerbation with eosinophil and several n asthma in ing lncl ras In trials. clinical asthma. ,
blocking (combinations
the long the benralizumab ult f life of quality
that anti that -
IL5 p therapies including itrakinra 150 , and Current cut
ing , even a even
IL -
more mAb, were term - -
4Rα - 400 offs has IL IL 5 5 ;
This article isprotected rights by All copyright. reserved. ‘periostin lebrikizumab, with uncontrolled studies 2 phase In quantified side basolateral T2 with together Periostin, utilitytheir to identify asthma in studies III and II phase H IL dupilumab is in control asthma dupilumab with treatment moderate dupilumab to FeNO eosinophi blood of increase eotaxin for questioning weeks 4 every mg 300 of dose a at severeexacerbationreduced improv although LABA, seco with asthma by followed LABA of withdrawal FEV in improvement respectively), 44%, vs (6% placebo to compared 2 phase first the In therefore guide pitrakinra treatment. in polymorphisms 22 (from exacerbations decreased trial controlled inhibits Pitrakinra uman 13 -
Accepted Article rvn asthma driven responders d hs 2 phase nd target ,
serum ( - ised chemotaxiseosinophil for needed is 3 -
to in serum ed ) - sputum or blood eosinophilia (≥3% and ≥ 300 ≥ and (≥3% eosinophilia blood or sputum
eee uncontrolled severe periostin mAb asthma (70,166)
therapies
(164) ( registration phase in several countries.
RCT study f h epithelium the of (167,168)
IL patients IL targeting (68) ) . R genotypes 4Rα
R b cmeig with competing by 4Rα stud Plasma e Plasma
in moderate to severe ast severe to moderate in potential responders
showed ; and/ n ains ih notold sha n medium on asthma uncontrolled with patients in
ing . this CLCA1
y
, ls in the early treatment phase phase treatment early the in ls or
FEV upon s reduc requires further investi further requires hl rdcn ssei cort systemic reducing while reduction significant showed dupilumab
IL irrespectiveblood eosinophilcount of
DPP otaxin
rae ipoeet n FEV1 in improvement greater 13 and 1
. ICS in ed In these studies, several studies, these In
i my diffuse may it , IL - lbiiua ad tralokinumab) and (lebrikizumab 4
serpinB2 sha n corticosteroid and asthma 13
(165) those -
- m taper dose eee xcrain ad improve and exacerbations severe 5 t 1% i sbes f ains ih specific with patients of subsets in 11%) to 25% 3 is significantly suppressed by dupilumab treatment. As treatment. dupilumab by suppressed significantly is 3 ay serve as as serve ay stimulation
Pamcgntc rfln o these of profiling Pharmacogenetic .
to ih lo esnpis ≥300 eosinophils blood with , ,
IL is suppression of eotaxin of suppression IL blood 13 hma showed th showed hma ing
co 4. - no h bloodstream the into potential -
targeting rtopcie nlss f a of analysis retrospective A upregulated in upregulated and discontinuation in moderate to severe to moderate in discontinuation and (39,169) gation.
eosinophil count as a possible biomarker possible a as count eosinophil -
high’
b
(165) cells
iomarkers have been evaluated for evaluated been have iomarkers In
biomarker cseod use icosteroid therapy. ad FeNO (and .
A two recent phase III studies III phase recent two at pitrakinra at /µL, respectively) /µL, s periostin is is periostin s (70) . -
eedn severe dependent Based on its mode of action, of mode its on Based airway s
Ti ws elctd in replicated was This . at
- 3 results in a paradoxicala in results 3 1 ae en vlae in evaluated been have s
s all dose all and ACQ and
to identify respondersidentify to n xcrain rate exacerbation in - and
high) d -
cells high epithelial cells epithelial
ug ucin and function lung
dose (168) a teeoe be therefore can /µL, secreted regimen ICS patients - patients 5 scores after scores 5 -
(163) dependently . randomized
dupilumab dose Presently, asthma,
. except t the at s In the In might
from with plus , in s
This article isprotected rights by All copyright. reserved. biomarkers of irrespective decrease dramatic produced tezepelumab uncontrolled 584 in study airway Th challenge atopic T2 both correlates biopsies bronchial in expression TSLP OX40 including consider thus is inflammation and airways lower and upper and defence immune Thymic TSLP target decline in asthma patients on levels targeting treatment to responders identify to ability its from Apart improvements in asthma exacerbation rate, FEV periostin tralokinumab, with FEV and rate exacerbation study in improvements 2 phase a In blood eosinophilia (≥300 consistent demonstrate to failed asthma uncontrolled in II) exacerbations LAVOLTA against protection and I (LAVOLTA trials 3 redu phase greater subsequent a had also patients high seco a and ICS receiving patients asthma severe uncontrolled
Acceptedese - Article cytokines L on
have the potential to predict future predict to potential the have asthma patients asthma anti response S
tromal , while , DCs fibrob cells, mast - nlmaoy effect inflammatory to ed
(173)
(175) guide driving
therapies
blood s L the
ymphopoetin to inhaledto . Tetet ih anti with Treatment . anti While c While allergen a
T
significantly reduced FeNO and blood eosinophils blood and FeNO significantlyreduced eos recent asthma target. asthma recent h - 2 cell differentiation2 cell
TSLP cells
inophil at and lasts
sha patients asthma cells epithelial in found mainly is expressiononstitutive allergen - prolonged induced /µL)
treatment
s (TSLP
w
(170) numbers ere
(176) ) is an important cytokine centrally involved in first line first in involved centrally cytokine important an is ) ASM eosinophil response in sputum w sputum in response eosinophil
soitd ih reduc with associated ICS .
in subsequent clinical
to i svr exacerbations severe in ction asthma exacerbationsasthma -
. TSLP a also can i eaebto rts cos l ds regimen, dose all across rates exacerbation in s T
treatment
1
hese data have been repl been have data hese (177) n eim r ih oe ICS dose high or medium on
(174) TSLP (171) 1 , ACQ (AMG157/tezepelumab) . . mediate d an ed . I .
Future produce TSLP. TSLP. produce - n this study study this n
(172) 6 and AQLQ - with ih ains hwd non showed patients high
with s ptem “ upstream
.
disease severity and severity disease
research
allergic responses in the skin, gut skin, the in responses allergic in in tions nd controller and the periostin the and controller nd
studies
ih eisi (> periostin high and also reflected greater FEV greaterreflected also and DPP (171) hs cytokine This IL icated in another phase IIphase another in icated
. hud ep o identify to help should - oh h ery n late and early the both m
4 13, as completely blocked. completely as . -
pre se sic” f T2 of switch” aster
high patients show patients high (71) n chr o mild of cohort a in
increased - ls LABA plus
and .
oee, two However, 0 gm) or ng/mL) 50
e post
xpression of xpression upregulate , -
other cellsother significant
periostin - allergen where , ed s 1 - - ,
This article isprotected rights by All copyright. reserved. migratio and airways, the to recruitmentneutrophil on effect indirect its IL IL serious infections re show AQLQ refractoryasthma asthma in demonstrated ASM factor necrosis Tumor Anti NON responding into blood with antagonist CRTH2 years) ≤40 (age asthma, younger in effective most moderate appeared in study a of analysis hoc outcomes clinical several in improvements eosinophilic (e with line possiblyphases,development later in failed antagonists decreasing concept studies, CRTH2 antagonists cells inflammatory are C CRTH2 antagonists
eotrcat eetr oooos oeue xrse o T2 el (RH) antagonists (CRTH2) cells Th2 on expressed molecule homologous receptor hemoattractant 17RA is athesubunitis 17RA of receptorforIL17A osinophilic Accepted17 versible Article
- on CRTH2) or (DP2 receptor D2 prostaglandin the with interacting molecules small
- RA p TNF ed TYPE TYPE 2 TARGET
cells hase 3 studies studies 3 hase (99)
and a longer time longer a target
target airway emerging . eosinophili T to these Post and healthy controls healthy ) ( odtos including conditions, of n
h asthma ed )
2 - ed hoc analysis of analysis hoc BAL and bronchial biopsies bronchial and BAL - niety i icesd ptm neutrophils sputum increased via indirectly
obstruction therapies led to discontinuation of the cytok showed ASM
therapies including targeted drugs
evidenc - hc sol hl t cnoiae phenoty consolidate to help should which to a ED
(182) (TNF) ns esnpis n IE synthesis IgE and eosinophils ines,
( - cell ≥250 first
TREATMENT
beneficialeffect s, ,
o a upregulat an of e
-
(189)
(1 h lymphocytes Th2 exacerbation more
a been has cells/ thereby
90) a phase II phase a . .
. blocked blocked legc and/or allergic A placebo A eety se recently, However, overall insufficient efficacy and the occurrence of L)
induc associated (79) s
study with golimumab with study
(79,183 compared to compared on allergic responses downstream of theTh2 , IL17F, . Currently, several CRTH2 antagonists CRTH2 several Currently, .
ing of patients with patients of - anti lungfunction, controlled trial with etanercept for 10 weeks 10 for etanercept with trial controlled ed ILC2s , ea CT2 naoit hv be tse in tested been have antagonists CRTH2 veral
AHR
-
TNF programTNF G2 aha i svr ucnrle T2 uncontrolled severe in pathway PGD2 – with with and
187) refractory patients with patients A sc i i an is it such As .
n eosinophils and
due to due IL
placebo in placebo AHR .
25 (alsonamed25 Using multiple biomarkers in a post a in biomarkers multiple Using
IL (180,181) airwayhyperreactivity (
17A can can 17A both severe asthma severe unselected eosinophilic
pes (99,190)
in severe persistent asthma persistent severe in
(188)
uncontrolled, through a subgroup of patients withpatients of subgroup a and OC Hwvr mn CRTH2 many However, . increase the contractility the increase 000459 . (178,179)
.
adequate IL
study population study nrae TNF Increased trcie agt for target attractive 17E). its compared to compared asthma iet fet on effect direct
( atopic I Timapiprant . n additionto biomarkers are moving are of proof In , AHR
- pathway showing asthma )
, mild s. was and
In in ) - ,
This article isprotected rights by All copyright. reserved. pulse radiofrequency localized a involving intervention Acceptedthermoplasty Bronchial Bronchial thermoplasty TREATM withpatients asthma (197) LABA asthma persistent subgro a in respiratorylower andtractinfections, ( azithromycin double two in assessed improvement sputum in reductions 8 placebo, to Compared in evaluated was that macrolide first show and non and antimicrobial both possess Macrolides ArticleMacrolides targets in therapy IL17RA counts, asthma uncontrolled with (192) the is CXCR2 CXCR2 antagonist significant neutrophilic
. Remarkably, . . produced Two placebo Two neither ENT
ed asthma
efficacy up with non with up
clinical effectiveness in distinct asthma populations asthma distinct in effectiveness clinical s asthma. S high
26 weeks, 26
n QQ without AQLQ in TARGETING AIRWAY REMODELING
, these findings these , stud significant improvement in improvementsignificant
and furthe , -
s on clinical parameters including affinity azithromycin ( azithromycin - these beneficial effects were seen in seen were effects beneficial these
y controlled trials wit trials controlled .
ol demonstrate could etohl and neutrophils However, - - eosinophilic asthmaeosinophilic (BT) ln placebo blind
250mg 3 times a week; n=109) week; a times 3 250mg
receptor of receptor (193,194) r research should clarify this. week is a is
challenge affecting s anti 48 weeks, 48 relatively
of . - IL therewasa significant improvement endpoints in clinical - Despite IL otold trials. controlled
IL treatment 7 ramn wt boaua showed brodalumab with treatment 17 placebo a h 8, which is a known ch known a is which 8, 8
a crucial a lncl effectiveness clinical CXCR2 antagonists CXCR2 sha oto o ln fnto. ztrmcn was Azithromycin function. lung or control asthma levels
both (196) novel method that ablates that method novel 500m
dose - anti moderate and severe and moderate .
. - g hs efcs were effects These In trial controlled asthma orcontrol lung functi ih clarithromycin with role of neutrophil of role -
m depe 3 times a week; n= week; a times 3
a recent study recent a icrobial (‘’anti icrobial both Alt
dn rdcin i bod neutrophil blood in reductions ndent failed to reduce sev reduce to failed
og i t in hough (198) eosinophilic and non and eosinophilic have been conducted in patients in conducted been have . emo n ie with line In
(195) . Further in -
(AMAZES) inflammatory’’) - attractant for neutrophils for attractant s
e is suy (AZISAST) study first he
. exacerbations and AQLQ and exacerbations paralleled ercoy asthma refractory as potential therapeutic potential as 420) Clarithromycin ASM produced
vdne suggests evidence
on top of top on studies y bronchoscop by ere exacerbations ere
in uncontrolled in on
by -
(191) eosinophilic
overall properties s significant ih anti with ignificant
ICS ICS was the was .
(89) plus no ic - .
This article isprotected rights by All copyright. reserved. therapy, option. good a be might treatment eosinophilic l eosinophil high concomitant with anti from s asthma, allergic severe In the individual profile sputum identify to E individual patient. traits‘treatable or phenotypicfeatures other to relate a on consensus no is there levels eosinophil blood higher by defined inflammation, ha well been has antagonists) CRTH2 IL5, an e far, So identify point need clinicians cost and efficient For Concluding remarks recommendationsand exacerbations refractory affect not did BT studies, and visits department emergency severe BT after controlledstudyshow(AIR2) versus showed improved symptoms, treatment BT upon epithelium bronchial effectiveness clinical additional osinophilic asthmaosinophilic
Acceptedve Article inflammatory phenotype responsive to corticosteroids and anti and corticosteroids to responsive phenotype inflammatory
en salse, s established, been
standard care standard sha patients asthma ing mRNA analysis osinophilic asthma osinophilic
FeNO - (202)
IgE therapy, but it cannot predict the degr the predict cannot it but therapy, IgE
the phenotypes and endotypes ains ih a with patients
without seems presently the best biomarker evaluatedas following the SAVED approach T2 . rcn 3 recent A -
endotype is FeNO, while in more sophisticated settings, serum cytokines serum settings, sophisticated more in while FeNO, is endotype
comprises different endotypes. Currently, the best best the Currently, endotypes.different comprises
, while serum periostin and D - in symptomatic patients on high dose ICS and LABA and ICS dose high on patients symptomatic in effective
- signs ofairway inflammation of as part of multidimensional endoty
AR: =9; A2 n=190) PAS2: n=190; (AIR2: - ubanalyses care,
unique ug function. lung - including associated comorbidities (e.g., nasal polyposis, NERD) polyposis, nasal (e.g., comorbidities associated including rm oa IE s sfl in useful is IgE total erum er follow year ed reduceded severeasthmaexacerbations workreducedof and loss o PC20 low asthma
adoption well from
lower limit value limit lower hospitalizations - eie ad eibe imres to biomarkers reliable and defined
hw a show control, quality mild and exacerbations oflife less evels
concomitant of asthma - defined.
- of targeted treatment options treatment targeted of up n/r opoie ln function lung compromised and/or rm a From (199) h rmi ucnrle, wthn t a anti an to switching uncontrolled, remain who fe BT after overall n
Although no absolute no Although most likely to respond .
P
rcia prpcie including perspective practical o guide To Two P bain of ablation versus are likely to be eligible for BT n - ee of response after treatment. In patients In treatment. after response of ee 4 ha ’ or
nlss f w chrs of cohorts two of analysis
n
better response in patients patients in response better hwd eue svr exacerbations, severe reduced showed
or to concomitantmedicatio to or
dniyn ptet who patients identifying . Apart from these observations, so far so observations, these from Apart . on uncontrolled ve not been fully validated
p the year prior to BT to prior year the ing may helpto further characterize how
anti sensory exactly - L/3 agtd (endotypic) targeted IL4/13 - IL5 targeted therapy targeted IL5 /consisten
studies
in daily clinical practice clinical daily in point (13,204) ev fibers nerve blood eosinophil levels eosinophil blood
(200,201) - upr te in them support of RS ad AI and (RISA -
care . (203) t with
(204) cut off value off cut ol benefit could symptomatic biomarker . n within anwithin n
ih more with
biomarker with
. .
frequent A In these In . after
sham n the in (anti BT R) or as s . s
- - - , ,
This article isprotected rights by All copyright. reserved. Med.Care 2009;181(4):315 P 4. neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875 induced s 3. 800. 2. 56. 1. References KK Conflict of interest for financial support (travelling to task force meetings). authorsThe wish A elderly follow longitudinal as well as therapy targeted stability/ their and more include needs unmet Other options. T2 been has asthma pathways treatments targeted with conjunction progres recent Despite henotypes Using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Crit c
kn Accepted Article asthma still represents an unmet need lacking adequate biomarkers and targeted treatment targeted and biomarkers adequate lacking need unmet an represents still asthma was
reliable
owledgement:
asthma patients Moore Moore MeyersWC, DA, Wenzel SE, Teague WG, Li H, et Li X, al. Identification of Asthma Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of A,Papi Brightling C,Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783 Lambrecht BN, an employee and shareholder of Novartis until 31 October
putum in adults asthma:with identification ofsubgroup with isolated sputum and
(composite) validate behaviour
fairly
and administration rou administration and to thank the European Academy of Allergy and Clinical Immunology (EAACI)
Hammad H. The immunology ofasthma. Nat Immunol. 2015;16(1):45 well
associated biomarkers for biomarkers associated (>60 years) i te dniiain of identification the in s
vr ie I prle, cness n ramn agrtm (which algorithms treatment on consensus a parallel, In time. over biomarkers - – characterized 323. - up of response to novel to response of up
differentiating and , t , ih well with
here is here pediatric te including clinically applicable biomarkersapplicableincluding clinically
for wh for still an unmet an still - defined
population
non , ich distinct te potentially other
patient biologic
- invas cut
asthma s - , ive
off . for how long how for
al need to characterize underlying characterize to need
, s in real in s values ipy measurable simply
2018. pheno
plcbe biomarkers applicable
n dcmnain on documentation and - /endo life settings life ) is urgently needed, urgently is ) types. – ,
validated , wh 9. , including , So far So
ile
non – , –
T2 in -
This article isprotected rights by All copyright. reserved. 18. 2018;141(4):1280 discovery using transcriptomic profiles in adult 17. severe asthma. EurRespir J. 2017;50(3). Transcriptomic gene signatures associated with persistent airflow limitation in withpatients 16. onProgram/BiomarkerQualif https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificati 15. 2017;151(2):455 Development in COPD: Moving From 14. Academy ofAllergy, Asthma & Immunology. J Allergy ClinImmunol. 2016;137(5):1347 document of theEuropean Academ medicine in patients with allergic diseases: Airway diseases and atopic dermatitis 13. Allergy. 2012;67(7):835 12. Immunol.Clin 2018;18(2):96 Biomarkers and asthma management: analysis and potential applications. Curr Opin Allergy 11. patients. Respir Res. 2017 23;18(1):39. Cluster analysis ofsputum cytokine 10. BIOPRED. Eur Respir J. 2017;49(2). and(Th2) non 9. Allergy ClinImmunol. 2014;133(5):1280 phenotyping ofSevere Asthma Research Program participants using expanded lung data 8. 2014;43(2):343 guidelines 7. Immunol. 2015;15(1):57 6. and Clinical Asthma Phenotypes. Am J Respi 5.
Accepted Article
Alexis Alexis BiomarkerNE. sampling ofthe airways in as Hek Hekking P FDA BiomarkerCDER Qualification Program [Internet]. Available from: Hollander Z, DeMarco ML, Sadatsafavi M, McManus BM, Ng RT, DD.Sin Biomarker A,Muraro Lemanske RF, Hellings PW, Akdis CA, Bieber CasaleT, TB, et al.Precision Agache I,Akdis JutelC, M, Virchow JC. Untangling asthma phenotypes a Richards LB, Neerincx AH, va Seys SF, Scheers H, Van den Brande P, Marijsse G, Dilissen E, Van Den Bergh A, et al. C Kuo W,BleeckerWu E,Moore BusseW, WW, Castro M, Chung KF, et Unsupervisedal. Chung KF, Wenzel SE, Brozek JL, A, Bush Castro M,Sterk PJ, et al.International ERS/ATS Fahy JV. Type 2 inflammation in asthma Haldar P, Pavord ID, Shaw DE,Berry MA, Thomas M, Brightling CE,et Clusteral. Analysis on definition, evaluation and treatment of severe asthma. EurRespir J. king P - HS, Pavlidis LozaS, M, Baribaud F, Rowe A, I, Pandis et al. T - Th2 molecular phenotypes of asthma using sputum transcriptomics in U – 73. – - - 67. – P, Loza MJ, Pavlidis S,de Meulder B, Lefaudeux D,Baribaud F, et al. Pathway P, Loza MJ, Pavlidis S, De Meulder B, Lefaudeux D,Baribaud F, et al. 90.
– – 846. 65. icationProgram/default.htm –
108. y ofAllergy and ImmunologyClinical and the American
-
high profileshigh reveals diversity in T(h)2 n Bragt JJMH, Sterk PJ, Bel EHD, Maitland P Values to Products to Impact Patient Care.Chest.
– 8. r Crit Care Med.2008;178(3):218
- -- onset severe asthma. J Allergy Clin Immunol. present in most, absent in many. Nat Rev
thma. Curr Opin Pulm Med.
- helper helper cell type 2 - high asthmahigh – - van der Zee AH. nd endotypes. 224. - PRACTALL
– - 58. . J
This article isprotected rights by All copyright. reserved. 8. by collection and mass spectrometric a 32. pulmonary disease. J Allergy ClinImmunol. 2016;138(4):970 31. Asthma.with J Am Respir CareCrit Med. 2010;181(10):1033 of Exhaled Nitric Oxide Measurement to Identify a Reactive, at 30. allergic rhinitis. Allergy. 2007;62(4):378 oxide: longitudinal reproducibility and the effects of anasal allergen challenge in patientswith 29. 2017;52(12):1616 Breathomics from exhaled volatile organic compounds in pediatric asthma. Pediatr Pulmonol. 28. exhaled NO in asthma diagnosis and mana 27. asthma?” J Asthma. 2012;49(8):807 26. rarely reflect airway eosinophilia in children with severe asthma. Allergy. 2013;68(3):402 25. systematic review and m accuracy ofminimally invasive markers for detection ofairway eosinophilia in asthma: a 24. asthmatics. Allergy. 2016;71(8):1192 consistently serve as the best predictors for the blood eosinophilia phenoty 23. eosinophil 22. eosinophils in asthma. Thorax. 2015;70(2):115 validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum 21. 2016;3:31324. signature in allergic asthmatics following allergen bronchoprovocation test. Eur Clin Respir J. 20. 20 19. 2014;20(1):46
Accepted Article17
;23(1):34 Almstrand A LD,Bos Sterk PJ, Fowler SJ Dweik RA, Sorkness Boo Neerincx AH, Vijverberg SJH, LDJ, Bos Brinkman P, van der Schee MP, de Vries R, et al. Ludviksdottir D, Diamant Z, Alving K,Bjermer L, Malinovschi A. Clinical aspects ofusing Spector Ullmann N,Bossley CJ, Fleming L, Silvestri M, Bush A, Saglani S. Blood eosinophil counts Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, et Diagnostical. Agache I, Strasser DS, Klenk A, Agache C,Farine H, Ciobanu et C, al. Serum IL Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink E Zuiker RGJA, Tribouley C, Diamant Z, Boot JD, Cohen AF, Van Dyck K, etal. Sputum RNA Seys SF. Roleof sputum biomarkers in the management ofasthma. Curr Opin Pulm ia in patientsia with severe asthma. J Allergy ClinImmunol. 2015;135(3):822 t JD, de Kam ML, Mascelli MA, Miller B, van Wijk RG, de Groot H, et al. Nasal nitric - –
40. SL, Tan RA. a Is single blood eosinophil count a reliable marker for “eosinophilic 52.
–
27. - C, Ljungström E,Lausmaa J, Bake B, Sjövall P, Olin A
eta - RL, Wenzel HammelS, J, Curran analysis. Lancet Respir Med. 2015;3(4):290 . Breathomics in the setting ofasthma and chronic obstructive – 10. – 202. nalysis of exh
– 84. gement. Respir Clin J. 2012;6(4):193
– 20.
aled aled particles. Anal Chem. 2009
- Everett D, Comhair SAA, et Useal. – – 1041. - 6. Risk Phenotype among Patients JM, Bel EH, et Externalal.
– - C. AirwayC. monitoring 300. pe in adult
– 207. - ;81(2):662 5 and IL
– 824.e2. – Med. 6. - 13
– This article isprotected rights by All copyright. reserved. Acceptedand inhaled corticosteroid response of eosinophilic and non 46. biomarkersfuture in allergic asthma. Allergy. 2016;71(4):475 45. 2018;73(4):837 Emerging roles of innate lymphoid cells in inflammatory disease 44. 2018 fraction 43. inflammation in nonallergic asthma. Med.Nat 2013;19(8):977 42. neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10): induced sputum in adults asthma:with identification ofsubgroup with isolated sputum 41. metric of Th2 airway inflammation in asthma. Clin Transl Allergy. 2013;3(1):24. 40. 2009;180(5):388 driven Inflammation 39. Immunol. 2014 expression in sputum cells can identify TH2 Article38. controlled asthma. Clin Exp Allergy J Br Allergy Soc ClinImmunol. 2013;43(9):1009 Sputum cytokine mapping revealsan “IL 37. biomarker for asthma. J Allergy ClinImmunol. 2017;139(1):1 36. 2015;135(1):25 35. management: Where do we sta pharmacogenomics, epigenomics, and transcriptomics to improve childhood asthma 34. Imaging. 2017;37(5):489 asparticles markers of small airway inflammation in subjects with asthma. PhysiolClin Funct 33.
;67:S3 Berry M, Morgan A, Shaw ParkerDE, D, Green R, Brightling C,et Pathologicalal. features Zissler UM, Esser Kortekaas Krohn I,Shikhagaie MM, Golebski K,Bernink JH, Breynaert C,Creyns B, et al. Soma T, Iemura H, Naito E, Miyauchi S, Uchida Y, Nakagome K, et Implicational. of Brusselle GG, Maes Bracke T, KR. Eosinophils in the spotlight: Eosinophilic airway Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw a J, Pavord ID. Analysis of Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, et Aal. qPCR Woodruff PG, Modrek B, Choy DF, JiaG, Abbas AR, Ellwanger A, et T al. Peters MC, Mekonnen ZK, Yuan S,Bhakta WoodruffNR, PG, Fahy J Seys SF, Grabowski M, Adriaensen DecraeneW, A, Dilissen E, Vanoirbeek JA, Trivedi A, Hall HoffmanC, EA, Woods JC, Gierada DS, Castro M.Using imaging a as Huang YJ, Boushey HA. The microbiome in asthma. J Allergy ClinImmu Farzan N, Vijverberg SJ,Kabesch M, Sterk PJ, Larsson P, Lärstad M, Bake B, Hammar O, Bredberg A, Almstrand A
of exhaled nitric oxide and blood eosinophil count in se – 11. ;133(2):388 – –
50. 30. – 395.
Defines Major Subphenotypes ofAsthma. Am J Respir Crit Med.Care
- – von Bieren J, Jakwerth CA, Chaker AM, Schmidt 97. - 94.
nd? Pediatr Pulmonol. 2018
- 5, IL - high and TH2 - 17A, IL Maitland - 25 - high” pattern associated with poorly - low subtypes of asthma. J Al
;53(6):836 - eosinophilic asthma. Thorax. – - – van der Zee AH. The use of – 10. 94. 9. vere asthma. Allergol Int. s: Clinicals: implications. Allergy.
- 845 - Weber CB. Current and V. Measures ofgene -
C, et C, Exhaledal. - nol. helper Type 2
875 –
et al. – 17. 9. - lergy Clin based
- This article isprotected rights by All copyright. reserved. Accepted60. 2014 evidence and future research needs for FeNO measurement in respirator 59. applications. Am J Respir CareCrit Med clinical practice guideline: interpretation of exhaled nitric 58. asthma. J Allergy Clin Immuno inflammatory heterogeneity with multi 57. 2017;12(7):e0180778. Endotypes of difficult 56. 2015 TH17 inflammatory pathways are reciprocally regulated in ast 55. ofahead print] eosinophil peroxidase on a lateralflow 54. 2016;138(6):1608 Individualized therapy for persistent asthma in young children. 53. ArticleRespir Med. 2015;3(11):824 52. matter? EurRespir J. 2014;44(1):14 51. 2014;44(1):97 concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 50. 2018. Available from: www.ginasthma.org 49. or oxide sputu review and meta 48. 2009;3(4):198 47. 2007;62(12):1043
;108(6):830 ;7(301):301ra129. Kostikas K,Minas M, Papaioannou AI, Papiris DweikS, RA. Exhaled nitric oxide in Bjermer L, Alving K,Diamant Z, Magnussen H, Pavord PiacentiniI, G, et Currental. Dweik RA, Boggs PB, Erzurum IrvinSC, CG, Leigh MW, Lundberg JO, et Anal. official ATS Agache I, Strasser Pierlot DS, GM, Farine H, Izuhara K, Akdis CA. Monitoring Brown KR, Krouse RZ, Calatroni A, Visness CM, Sivaprasad Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui et S, al. TH2 and Wolfe MG, Mukherjee M, Radford K, Brennan JD, Nair P. Rapid quantification ofsputum Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Mukherjee Kostikas K,Zervas E, Gaga M. Airway and systemic eosinophilia in asthma: does site Schleich FN, Chevremont A, Paulus Henket V, M, Manise M, Seidel L, et al. Impo 2018 GINA Report, Global Strategy for Asthma Management and Prevention [Internet]. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et Aal. systematic Gibson PG. Inflammatory phenotypes in adult asthma: m eosinophils).m Thorax. 2012;67(3):199 – –
108. 206. - – analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric 41. – – M, Nair P. Blood or sputum eosinophils to guideasthma therapy? Lancet 1618.e12. 9.
-
to
-
control asthma in inner – 5.
l. 2018
– ;141(1):442 6. ple biomarkers for multidimensional endotyping of . 2011 test test strip. Allergy. 2018.
;184(5):602 - – city African American children. One.PloS 5.
– 208. –
oxide levelsoxide (FENO) for clinical 15.
clinical applications. RespirClin J.
hma. Transl Sci Med.
doi: 10.1111/all.13711. [Epub J Allergy Clin Immunol. U, KercsmarU, CM,et al. y diseases. Respir Med. rtance of This article isprotected rights by All copyright. reserved. Acceptedplacebo tralokinumab in pa 73. Children. Curr Treat Options Allergy. 2016;3(4):439 72. Thorax. 2015;70(8):748 moderate 71. Lebrikizumab Treatment in Adults 70. and eosinophilic inflammation in poorly 69. Immunol. 2012;130(3):647 systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin 68. Immunol. 2013;43(11):1217 withpatients asthma using exhaled breath profiling. Exp Clin Allergy J Br Soc Allergy Clin 67. Allergy J Br Soc breath profiles in the monitoring ofloss of andcontrol recoveryclinical in asthma. Exp Clin 66. Article MedCare Electronic nose identifies bronchoalveolar lavage fluid eosinophils in 65. diagnostic label. Eur Respir J. 2018;51(1). inflammatory phenotyping by breathomics 64. randomised controlled trial. Lancet asthma in pregnancy guided b 63. Thorax. 2018 markers (exhaled nitric oxide or sputum eosinophils): a systematic review and met 62. smokers. Respir Med. 2010;104(6):917 hypertonicwith saline reduces fractional exhaled nitric oxide in chronic smokers and non 61. asthma in adults: the end theis beginning? Curr Med Chem. 2011;18(10):1423
Brightling CE, Chanez P, Leigh R,O’Byrne PM, Korn SheS, D,et al. Efficacy and safety of James A, Hedlin G. Biomarkers for the Phenotyping and Monitoring ofAsthma in Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer et SK, Lebrikizumabal. in Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Simpson JL, Yang IA, Upham JW, Rey G,Jia Erickson RW, Choy DF, Mosesova S, LC,Wu Solberg OD, etal.Periostin a is van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predicting steroid responsiveness in Brinkman P, van de Pol MA, Gerritsen MG, Bos LD, Dekker T, Smids BS, et al. Exhaled Fens van N, der Sluijs KF, van de Pol MA, Dijkhuis A, BS, Smids van der Zee JS, et al. de VriesR, Dagelet YWF, Spoor P, Snoey E, Jak PMC, Brinkman P, et al. Clinical and Powell H, Murphy VE, Taylor DR,Hensley MJ, McCaffery K, Giles W, et Managemental. of Petsky HL, Cates CJ, Kew ChangKM, AB. Tailoring asthma treatment on e Zuiker RGJA, Boot JD, Calderon PiantoC, - controlled, phase 2b Lancet trial. Respir Med. 2015;3(9):692 . 2015 - to - severe asthma: pooled data from two randomised placebo ;73(12):1110
;191(9):1086 Allergy Clin Immunol. 2017;47(9):1159 tients with severe uncontrolled asthma: a randomised, double – 56. - – 1119.
654.e10. –
– 25. y measurement of fraction of exhaled nitric oxide: a double 8.
with Asthma. N Engl J Med. 2011;365:1088 . 2011
– - 20. controlled asthma. BMC Pulm Med. 2016;16(1):67. ;378(9795):983
in chronic airway diseases irrespective of the nolds PN, Hodge James S, AL, et al. Periostin levels
ne A, Petty K,de Kam M, et al. Sputum induction – 52. – 69.
– 90.
– asthma. Am J Respir Crit 701. - controlled studies.
– – 1098. 31. osinophilic - blind, a
- analysis.
- - blind,
This article isprotected rights by All copyright. reserved. Obesity in asthma: more neutrophilic inflammation a as possible explanation for a reduced Accepted86. BMC Pulm Med. 2013 Inflammation and corticosteroid responsiveness in ex 85. Immunol. 2014;133(6):1557 are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin 84. and identification using induced sp 83. inflammation. BMC Pulm Med. 2013;13:11. phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic 82. insensitive asthma. J Am R exhaled nitric oxide and serum periostin a as composite marker to identify severe/steroid 81. trial. 2018Trials. algorithm to adjust corticosteroid dose versus standard care: protocolstudy for a pragmatic trial of corticosteroid optimization in 80. 2014;69(9):1223 response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 79. Articleresponsiveness. Allergy. 2017;72(8):1202 eosinophilic asthma using a multivariate prediction model based on blood granulocyte 78. really non sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics 77. Analysis. J Allergy ClinImmunol Pract. 2017;5(4):990 Leukotriene E4 to Determine Aspirin Intolerance in Asthma: A Systematic Review and Meta 76. Allergy. 2019 management of NSAID 75. Immunol. 1995;95(1 Pt 1):42 biosynthesis and allergen effect of MK 74.
Telenga ED, Tideman SW, Kerstjens H a.M, Hack Telenga ED, Kerstjens HAM, Ten Hacken NHT, Postma DS, van den Berge M. Moore HastieWC, AT, Li X, Li H, Busse WW, Jarjour et NN, Sputumal. neutrophil counts Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular Nagasaki MatsumotoT, H, Kanemitsu Y, Izuhara K, Tohda Y, Horiguchi T, et al. Using Hanratty CE,Matthews JG, Arron JR, Choy DF, Pavord BraddingID, P, et Aal. randomised Pettipher R, Hunter MG, Perkins CollinsCM, LP, Lewis BailletT, M,et al. Heigh Hilvering B, Vijverberg SJH, Jansen J, Houben L Demarche S, Schleich F Hag Kowalski ML, Agache I,Bavbek BakirtasS, A, Blanca M, Bochenek G, et al.Diagnosis and Diamant Z, Timmers MC, van der Veen H, Friedman BS, DeSmet M, Depré M, et Theal. - inflammatory? BMC Pulm Med. 2016;16:46. an JB, Laidlaw TM, Divekar R, O’Brien KitaEK, H, Volcheck GW, et Urinaryal. - 0591, anovel 5 ;74(1):28 ;19(1):5. – 32. ;13:58.
- - Exacerbated Respiratory Disease (N 39 - . induced airway responses in asthmatic subjects in vivo. J Al espir Crit Med.Care 2014
- lipoxygenase activating protein inhibitor, on leukotriene –
– 15 51. , Henket M, Paulus Van HeesV, T, Louis R. Detailed analysis of 63.e5.
utum. Respirol Carlton 2006;11(1):54Vic.
– 11.
severe asthma using a composite biomarker ;190(12):1449 – - , Schweizer RC, Go et DiagnosingS, al. , current 997.e1.
en NHTT, Timens W,Postma et DS, al.
- ERD)
-
and never - a EAACI positi – 52.
- smoking asthm – 61. on paper.
randomised
tened lergy Clin - atics. -
This article isprotected rights by All copyright. reserved. Acceptedof Tumor Necrosis Factor α in Refractory Asthma. N Engl J Med. 2006;35 99. asthma. J Allergy Clin Immunol. 2018;141(2):560 transcriptomics reveal upregulation of IL 98. 76. expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43(4):1067 97. Immunol.Clin 2014;133(4):997 expression signature of6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy 96. innate or adaptive immunity? Clinical implications. DevClin Immunol. 2013;2013:840315. 95. cells. Am J Respir MolCell 2002;26(6):748 Biol. related oncogene 94. 2018;73(10):2024 clusters reveal neutrophil 93. Allergy ClinImmunol. 2017;139(6):1819 Intraepit 92. ArticleImmunol. 2012;129(4):974 is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin 91. 2011;38(3):567 inflammatory phenotypes in adults and children with acute asthma. Eur Respir J. 90. airway inflammation in refractory asthma. Am J Respir Crit Med.Care 20 89. 2017;140(4):1004 biochemical correla 88. Pattern. Individuals with Asthma Preferentially Have aHigh IL 87. treatment response. Allergy. 2012;67(8):1060
Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et Evidenceal. ofaRole Rossios C, Pavlidis HodaS, Kuo U, C Simpson JL, Phipps S,Baines KJ, Oreo KM,Gunawardh Baines KJ, Si DMA,Bullens Decraene A, S, Seys Dupont LJ. IL Jones CE, Chan K. Interleukin M Su Andersson AdamsCK, A, Nagakumar P, Bossley C, Gupta A, DeVries D,et al. Bossley CJ, Fleming L, Gupta A, Regamey N, Frith Wang F, He XY, Baines KJ, Gunawardhana LP, Simpson JL, Li F, et Differental. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic R,Alam Good J, Rollins D, Verma M, H, Chu Pham T Marijsse GS, Seys SF, Schelpe A Am JAm Respir Crit Med.Care 2014 helial neutrophils in pediatric severe asthma areassociated withbetter lung function. J - W, LinW, W – 74. - alpha, and granulocyte – – tes of refractory neutrophilic asthma. J Allergy ClinImmunol. 32. 1014.e13. mpson JL, Wood LG, Scott RJ, Fibbens NL, Powell H, et al.Sputum gene
- C, TsaiC, C
- pr – 982.e13. edominant phenotype distinctwith gene expression. Allergy.
- – H, Chiang B 1007. - 17 stimulates the expression of interleukin
- S, S, Dilissen E, Goeminne P, Dupont LJ, et al
;189(10):1284 - – - colony 1 receptor 1829.e11. - H, Wiegman C, Russell K, et al.Sputum - L, Yang Y – – 8. - 53. stimulating factor by human airway epi –
70.
family members in patients with severe - -
- H, Lin Y 5/IL 17A in human respiratory diseases: –
J, Oates et PediatricT, al. severe asthma 5. -
H, et al.Airway and serum - 17A/IL ana L, Gibson PG. Elevated - T, et T, al. Childhood asthma - 25 Sputum Inflammatory 4(7):697 08;177(2):148 - . Obese 8, growth – 708.
– thelial 155. -
– This article isprotected rights by All copyright. reserved. membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 114. 113. 2003 alterations selectively associated with severe asthma. Am J R 112. asthmatic 111. 2006 damage and angiogenesis in the airways of children asthma.with Am J 110. Cr thickening ofthe reticular basement membrane in children difficultwith asthma. Am J Respir 109. artifact or pathology? Am J Respir CareCrit M 108. hypertrophy and hyperplasia in asthma. J Am R 107. changes in asthma. Eur Respir J. 2007;29(2):379 106. asthma: Comparison with different sp Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable 105. 2005;26(3):523 condensate: methodological recommendations and unresolved questions. Eur 104. altitude exposure. ExpClin Allergy. 2017;47(12):1675 sputum calprotectin, areflection of neutrophilic airway inf 103. systemic infla serum levels oftumour necrosis factor 102. factor for severe asthma. Respir Med. 2010;104(8):1131 101. 2014;7(5):1186 relationship between inflammation and lung function in severe asthma. Mucosal Immunol. 100.
Accepted it Care Med. 2003 Article
;167(10):1360 ;174(9):975 Ward PaisWard C, M, Bish R,Reid D, Feltis B, Johns D,et al. Airway inflammation, basement Y,Sumi Hamid Q. Airway remodeling in asthma. Allergol Int. 2007;56(4):341 Benayoun L, Druilhe A, Dombret M Roche WR,Beasley R, Williams JH, Holgate ST. Subepithelial fibr Barbato A, T Payne Rogers DNR, AV, Adelroth E, Bandi GuntupalliV, KK, Bush A, et Earlyal. Ordoñez C, Ferrando R, Hyde DM,Wong HH, Fahy JV. Epithelial desquamation in asthma: James AL, Elliot JG, Jones RL, ML, Carroll Mauad T, TR Bai Fixman ED, Stewart A, Martin JG. Basic mechanisms ofdevelopment ofairway structural Ntontsi P, Loukides S,Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E,etal. Horváth Hunt I, J, Barnes PJ, Alving K,Antczak A, Baraldi E,et Exhaledal. breath Decaesteker T, Seys S,Hox Dilissen V, E, Marijsse G, Manhaeghe L, et al. Serum and Silvestri M, Bontempelli M, Giacomelli M, Malerba GA,M, Rossi Stefano D,et Highal. Agache I, Ciobanu Agache C, C,Ang Manni ML, Trudeau JB, Scheller EV, Mandalapu Elloso S, MM, Kolls JK, et Theal. complex s. Lancets. Lond Engl. 1989 mmation? Clin Exp Allergy. 2006 – – 48. 98. – 81. – ;167(1):78 urato G, Baraldo Bazzan S, E, Calabrese F, Panizzolo C,etal. Epithelial
8.
– 82. ;1(8637):520
utum phenotypes. Allergy. 2017;72(11):1761 ‐ α and hel M. hel Increased serum IL - C, AubierC, M, Pretolani M. Airway structural interleukin ed. 2000;162(6):2324 ;36(11):1373 espir CareCrit Med. 2012 – – 89. 4.
– 7. – ‐ 8 in severe asthma: markers of 7. lammation in asthmatics after high
– espir Crit Care Med. 81. , et al.Airway smooth muscle
– - 9. 17 is an independent risk Respir CareCrit Med.
osis in the bronchi of ;185(10):1058
2002;57(4):309 Respir J.Respir – – 7. 8.
–
64.
- – This article isprotected rights by All copyright. reserved. 127. Acceptedasthma. Am J R Glucocorticoid 126. Allergy. 2014;69(9):1233 expression profiling oflaser microdissected airway smooth muscle tissue in asth 125. severe pediatric asthma. J Allergy ClinImmunol. 2013;132(2):328 chitinase 124. Physiol. 2011;73:479 chitinase/chitinase 123. 1998 down 122. omalizumab bronchial biopsies: galectin 121. treated with omalizumab for 36 early predictive biomarker of modulation of airway remodeling in patients with severe asthma 120. Articleexcessive airway narrowing. Exp Clin Allergy J Br Allergy Soc Clin Immunol. 2010;40(4):576 119. J Allergy ClinImmunol. 1997 Mar;99(3):330 budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. 118. 2007;30(3):457 byguided airway hyperresponsiveness in children: a randomised controlled Eurtrial. Respir J. 117. membrane of mild at treatment reduces deposition of ECM proteins in the bronchial subepithelial basement 116. 1999;159(4 Pt 1):1043 additional guide to long and histopathologic outcome ofasthma when using airway hyperresponsiveness anas 115. 16.
;161(1):385 - regulates IL Ammit AJ, Burgess JK, Hirst SJ, Hughes JM, Kaur M, Lau JY, et Theal. effect of asthma Yick CY, Zwinderman AH, Kunst PW, Grünberg K,Mauad T, Fluiter K,et al. Yick CY, Zwinderman AH, Kunst PW, Grünberg K,Mauad T, Chowdhury et S, al. Gene Konradsen JR, James A, Nordlund B, Reinius LE, Söderhäll MelénC, E, etal. The Lee CG,Da CA,Silva Dela CS,Cruz Ahangari F, MaB, Kang M Cortegano I, delPozo V, Cárdaba B, de Andrés B, Gallardo S, P, RiccioMauri AM, Rossi SilvestreR, Di D, Benazzi L, DeFerrari L, et al. Riccio AM, Mauri P, DeFerrari L, Rossi R, Di Silvestre D,Benazzi L, et Galecal. CS,Ulrik Di Booms P, Cheung D, Timmers MC,Zwinderman AH, Sterk PJ. Protective effect of inhaled Nuijsink M, Hop WCJ, Sterk PJ, Duiverman EJ, de Jongste JC. Long Flood Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control - like like protein YKL - treated severe asthma patients. Immunol Lett. 2014;162(1 Pt A):2 - Page P, Menzies - espir Crit Care Med.2013 induced changes in gene expression ofairway smooth muscle in patients with – 66. – - 9. amant Z. Add 5 gene expression on different cell types. J Im - like like
opic asthmatics. J Clin Invest. 2003;112(7):1029 – 501. – - proteins in inflammation, tissue remodeling, and injury. Annu Rev 51. term treatment. The AMPUL Study – - 40. 40: a possible biomarker of inflammation and airwa
-
3 as a 3 as predictive biomarker of airway remodelling modulation in -
Gow A, Phipps YingS, S,Wangoo A, Ludwig MS, et al.Anti
- months. Clin Transl Allergy. 2017;7:6. on montelukast to inhaled corticosteroids protects against ;18 7(10):1076 – 7.
– 84.
Group. AmJ Respir Crit Med.Care
munol Baltim Md 1950. – - 335.e5. del Amo A, et al. Galectin J, et al.Role ofchitin and – 36.
- term asthma treatment
y remodeling in
– Proteomics of 10. ma andma atopy.
tin - - 3: an IL - 5 – - 3 81.
This article isprotected rights by All copyright. reserved. and children. C 140. Med Insights Circ Respir Med.Pulm 2012;6:27 139. R 138. rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72(8):1156 Biomarkers for monitoring clinicalefficacy ofaller 137. 2015;70(7):727 Biologicals task force paper on the use ofbiologic agents in allergic disorders. Allergy. 136. 83. confocal laser endomicroscopy in pulmonary diseases. Curr Opin Pulm Med. 2017;23(3):275 135 f wall in asthma: fibered confocal fluorescence microscopy in relation to histology and lung 134. marker of mucosal remodelling in chronic rhino 133. periostin in steroid 132. 2004 treatmentterm with inhaled corticosteroid on airway wall thickening 13 asthma. ExpClin Allergy J Br Allergy Soc ClinImmunol. 2005;35(10):1361 matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in 130. AllergyBr Soc ClinImmunol. 2007;37(7):1067 asthma from rhinitis patients with or without bronchial hyperresponsiveness. ClinExp Allergy J 129. 2006;130(1):58 following deep inspiration after a course ofhigh 128. PharmacolPulm Ther. 2009;22(5):446 therapeutics on signalling and transcriptional regulation of airway smooth muscle function. unction. Respir Res. 2011; espir Crit Med.Care 2001
Accepted Article1.
.
;116(11):725 Normansell R,Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults Thomson NC, Chaudhuri R. Omalizumab: clinical use forthe management ofasthma. Clin Busse WW. Anti Shamji MH, Kappen JH, M,Akdis Jensen Boyman O, Kaegi C,Akdis M, Bavbek BossiosS, A, Chatzipetrou A, et EAAal. Wijmans L, d’Hooghe JNS, Bonta PI, Annema JT. Optical coherence tomography and Yick CY, von der Thüsen JH, Bel EH, Sterk PJ, Kunst PW. In vivo imaging ofthe airway Ebenezer JA, Christensen JM, Oliver BG, Oliver RA, Tjin G, Ho J, et Periostinal. a as Hoshino M,Ohtawa J, Akitsu K.Association of a Niimi A, Matsumoto H, Amitani R, Nakano Y, Sakai H, Takemura M,et Effectal. of short de Kluijver J, Schrumpf JA, Evertse CE, Sont JK, Roughley PJ, Rabe KF, et Bronchialal. Tufvesson E, Aronsson D, Bjermer L. Cysteinyl AM Slats ochra – – , Sont JK, van Klink RHCJ, Bel EHD, Sterk PJ. Improvement in bronchodilation 54. 65. – - 31. naive asthma. Allergy Asthma Proc. 2016;37(3):225 ne Database Syst Rev. 2014
- immunoglobulin E (omalizumab) therapy in allergic asthma. Am J 2(1):85. ;164(8 Pt 2):S12
– 54. -
17 – – . - 40. Jarolim E,Knol EF, Kleine 73.
sinusitis - ;(1):CD003559. dose oralprednisone in asthma. Chest. gen immunotherapy for allergic
- leukotriene levels irway wall thickness with serum . Rhinology. 2017
in asthma. Am J Med. –
in sputum differentiate 30. - ;55(3):234 Tebbe J, et al. – 9.
CI IG – 41.
– 73. – -
This article isprotected rights by All copyright. reserved. the lateasthmatic response. Lancet interleukin 155. Database Syst Rev. 2017 21;9:CD010834. 154. Immunol.Clin 2013;132(5):1086 benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy 153. and Exacerbations ofRefractory Eosinophilic Asthma. EnglN J Med. 2009;360 152. 2009;360(10):985 151. Allergy ClinImmunol. 2016;138(1):292 multidomain assessment of steroid response for predicting clinical response to omalizumab. J 150. exacerbations. J Allergy Clin Immunol. 2015 treatment with either omalizumab or an inhaled corticosteroid boost to prevent fallasthma 149. R effects of omalizumab in allergic asthma: an analysis ofbiomarkers in the EXTRA study. Am J 148. treatment ofallergic asthm 147. 536.e1. asthma: an update on recent developments. J Allergy ClinImmunol Pract. 2014;2(5):525 146. IgE in severe asthma patients treated omalizumab.with Respir Med. 2012;106(11):1494 145. specific IgE and the response to omalizumab therapy. Allergy. 2009;64( 144. and children. Cochrane Database Syst Rev. 2014;(1):CD003559. 143. asthma in children. Cochrane Database Syst Rev. 2018 08;3:CD012393. 142. Prospective Real Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A 141. Acceptedespir Crit Article
Leckie MJ,Leckie ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls et CM, al. Effects ofan Farne Laviolette M, Gossage DL, Gauvreau G, Leigh R,Olivenstein R, Katial R, et al.Effects of Haldar P, Brightling CE,Hargadon B, Gupta S, Monteiro SousaW, A, et Mepolizumabal. P. Nair Mepo Fleming L, Koo M,Bossley CJ, Nagakumar P, Bush A, Saglani TheS. utility ofa Teach MA,SJ, Gill Togias A, Sorkness CA, Arbes SJ, Calatroni A, et Preseasonalal. Hanania NA, Wenzel Rosén S, K, Hsieh H Johansson SGO, Lilja G, Hallberg J, NoppA. A clinical follow Humbert M, Busse HananiaW, NA, Lowe PJ, Canvin Korn S,Haasler FliednerI, F, Becher G, Strohner P, Staatz A, et Monitoringal. freeserum Wahn U, Martin C,Freeman P, Blogg P. M, RelationshipJimenez between pretreatment Normansell R,Walker S, Milan SJ, Walters EH, Nair AkhbariPike KC, M, Kneale D,Harris KM. Interventions for autumn exacerbations of Casale TB, Luskin AT, Busse W,Zeiger RS, Trzaskoma B, Yang M, et al.Omalizumab
- Care Med.Care 2013 5 blocking monoclonal antibo
HA, Wilson A, Powell C,Bax L, Milan SJ. Anti - World Study. J Allergy C – 993. lizumab for Prednisone
;187(8):804 a monitored by CD – 1096.e5. . 2000 – – 11. 4. lin Immunol 2019 Pract. ;356(9248):2144 dy on eosinophils, airway hyper
;136(6):1476
- Dependent Asthma with Sputum Eosinophilia. - sens. Immun Inflamm Dis. 2018;6(3):382 - J, Mosesova ChoyS, DF, et Exploringal. the – - IL5 therapies for asthma. Cochrane 85. P. Omalizumab for asthma in adults –
J, Erpenbeck VJ, et al.Omalizumab in 8.
;7(1):156 - up of omalizumab in routine 12):1780
- responsiveness, and - 164.e1. (10):973 – 7.
– 984. – – – 91. 500.
This article isprotected rights by All copyright. reserved. wide profiling identifies epithelial genescell associated withasthma and with treatment Accepted169. Dupilumab in Glucocorticoi 168. and Safety in Moderate 167. placebo tralokinumab in patients with severe uncontrolled asthma: a randomised, double 166. Polyposis: A Randomized Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal 165. controlled pivotal phase 2b dose inhaled corticosteroids plus a long safety in adults with uncontrolled persistent 164. persistent asthma with elevated eosinophil l 163. and Safety in Moderate 162. receptor αantagonist. polymorphisms predict reduction in asthma exacerbations during response to an anti Article161. Lancet Lond Engl. 2012 severe eosinophilic asthma (DREAM): a multicentre, double 160. Respir Med. 2015;3(5):355 multicentre, parallel, double for inadequately controlled asthma with elevated blood eosinophil counts: results from two 159. treatment in patients with severe eosinophilic a 158. 2014 glucocorticoid 157. JAm Respir Crit Med.Care 2007;176(11):1062 to Evaluate Safety and ofEfficacy Mepolizumab i 156.
;371(13):1189 Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly et GenomeS, al. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, L,Sher et al. Efficacy and of Safety Castro M,Corren J, Pavord MasperoID, J, We Brightling CE, Chanez P, Leigh R,O’Byrne PM, Bachert MannentC, L, Naclerio RM, Mull Wenzel CastroS, M, Corren J, J, Maspero Wang L, Zhang B, et Dupilumabal. efficacy and Wenzel FordS, L, Pearlman D,Spector S, L,Sher Skobier Castro M,Corren J, Pavord MasperoID, J, Wenzel S, Rabe KF, et al.Dupilumab Efficacy Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et IL al. Pavord ID,Korn S,Howarth P, Bleecker ER, Buhl R, Keene ON, et Mepolizumabal. for Castro M,Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab Ortega HG, Liu MC, Pavord BrusselleID, GG, FitzGerald JM, Chetta A, et Mepolizumabal. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene Yancey ON, et al.SW, Oral Flood - controlled, phase 2b Lancet trial. Respir Med. 2015;3(9):692 - Page P, Swenson C, Faiferman MatthewsI, J, Williams M, Brannick L, et Aal. Study - sparing effect of mepolizumab in eosinophilic a – 97. J Allergy ClinImmunol. 2012 - - ;380( to to
Clinical Clinical Trial. JAMA. 2016 - - Severe Uncontroll Severe Uncontroll – d - 66. - 9842):651 blind, randomised, placebo Dependent Seve
- ranging tri - acting β2 agonist: a randomised double – 9.
al. Lancet.al. 2016 evels. EnglN J Med. 2013 ed Asthma. NEngl J Med. 2018 ed Asthma. NEngl J Med. 2018 asthma despite use of medium re Asthma. NEngl J Med. 2018 – sthma. EnglN J Med. 2014 ol J, Ferguson BJ, Gevaert P, et al.Effect of 1071. n Patients with Moderate Persistent Asthma. ;315(5):469 ;130(2):516 nzel S, Rabe KF, et al.Dupilumab Efficacy Korn SheS, D,et al. Efficacy and safety of
- controlled, phase
- ;388(10039):31 blind, placebo sthma. EnglN J – – anda F, et al. Dupilumab in 79. 522.e4.
– ;368(26):2455 701.
;371(13):1198 - - 3 trials. Lancet
;378(26):2486 ;378(26):2486 controlled tria blind placebo - – ;378(26):2475 to 44. Med. - high
- - 4 receptor blind, - – dose 66. - IL - –
- 4 l. 207. – – – 96. 96. 85.
-
This article isprotected rights by All copyright. reserved. Accepted ExpClin Allergy. 2014;44(8):104 selective CRTH2 antagonist, reduces allergen 181. 2013;41(1):46 the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 180. molecule expressed on TH2 cells. J Allergy ClinImmunol. 2014;133(4):1184 activates group 2 innate lymphoid cells through chemoattractant receptor 179. transmembrane recept selectively induces chemotaxis in helperT type 2 cells, eosinophils, a 178. Uncontrollwith 177. 2014 anti 176. 2005 Th2 lymphopoietin expression increased is in asthmatic airways and correlates with expression of 175. 43. Articleallergic disorders 174. 2012;91(6):877 thymic stromal lymphopoietin (TSLP) during allergic inflammation and be 173. J Allergy ClinImmunol. 2013;132(2):305 periostin associates with greater airflow limitation in 172. placebo tralokinumab in patients with severe uncontrolled 171. Respir Med. 2016;4(10):781 LAVOLTA II): rep Efficacy and safety oflebrikizumab in patients with uncontrolled asthma (LAVOLTA I and 170. response to
- - TSLP TSLP antibody on allergen attracting chemokines and disease severity. J Immunol
;370(22):2102 ;174(12):8183 Diamant Z, Sidharta PN, Singh D,O’Connor BJ, Zuiker R, Leaker BR, et Setipiprant,al. a Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, et al. Inhibition of L,Xue Salimi M, Panse I, Mjösberg JM, McKenzie ANJ, Spits H, et al. Prostaglandin D2 H,Hirai Tanaka K, Yoshie O, Ogawa K,Kenmotsu K, Takamori Y, et Prostaglandinal. D2 Corren J, Parnes JR, Wang L, MoM,Roseti SL, Griffiths JM Gauvreau GM, O’Byrne PM, BouletL Ying S,O’Connor LiuIto T, Y Roan F, Bell BD,Stoklasek TA,Kitajima M,Han H, Ziegler SF. The multiple facets of Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, et al.Increased Brightling CE, Chanez P, Leigh R,O’Byrne PM, Korn SheS, D,et al. Efficacy and safety of Hanania NA, Korenblat P, Chapman KR, Bateman KopeckyED, P, Paggiaro P, et al. - controlled, phase 2b Lancet trial. Respir Med. 2015;3(9):692 corticosteroids. Proc – ed Asthma. Engl N J Med. 2017 52. – 86. licate, phase 3,randomised, double -- - TSLP programs the “Th2 code” in dendritic cells. Allergol Int. 2012;61(1):35 J, Arima K. Cellular and molecular mechanisms of TSLP function in human
– –
10. 90. or CRTH2. J Exp Med. 2001
B, Ratoff J, Meng Q, MallettK,Cousins D,et al. Thymic stromal – 96. - induced asthmatic resp
4
Natl AcadNatl Sci US A. 2007 – 52.
– 312.e3. - P, Wang Y, Cockcroft D,Bigler J, et al.Effects of an - induced airway responses in allergic asthmatics. ;377(10):936
;193(2):255 asthma: a randomised, double - blind, placebo
patients receiving inhaled corticosteroids. onses. NEngl J Med. ;104(40):15858
– Baltim Md 1950. 46. – 61. , et al. Tezepelumab in Adults
- controlled trials. Lancet nd basophils via seven – 701. - yond. J Leukoc Biol. – homolo
63. – 94. . EurRespir J.
- blind, gous - – This article isprotected rights by All copyright. reserved. medications: proposed mechanisms ofaction. Pharmacol Ther. 2008;117(3):393 195. double CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, 194. placebo of aCXCR2 antagonist in patientswith severe asthma and sputum neutrophils: a randomized, 193. diseases: can we target them and how? EurRespir J. 2010;35(3):467 192. moderate to severe asthma. J Am placebo 191. Se Randomized, Double 190. Thorax. 2005;60:1012 (TNFα)factor a as novel therapeutic ta 189. hyperresponsiveness by tumour necrosis factor 188. asthma: time for reappraisal. 187. Med. 2016;4(9):699 single prostaglandin D2 receptor 2 antagonist, in patients persistentwith eosinophilic asthma: a 186. uncontrolled on low Fevipiprant, an oral prostagl 185. inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37 an oral CRTH2 antagoni 184. AZD1981 in adults with asthma. Drug Des Devel Ther. 2016;10:2759 183. Immunol. 2013;131(6):1504 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin 182.
Acceptedvere Persistent Asthma. Am J Respir Crit Med.Care 2009;179(7):549 Article
- centre, randomised, double - S O’Byrne P P, Nair Gaga M Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway Busse WW, Holgate KerwinS, E, Chon Y, Feng J,J, Linet al.Randomized, double Wenzel BarnesSE, PJ, Bleecker ER, Bousquet J, Busse W, Dahlen S Howarth PH, Babu KS, Arshad LauHS, L, Buckley M, McConnell et W, al. Tumour necrosis Anticevich SZ, Hughes JM, Black JL, Armo Diamant Z, Aalders W,Parulekar A, Bjermer L, Hanania NA. Targeting lipid mediators in Gonem BerairS, R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, et al.Fevipiprant, a Bateman ED, Guerreros AG, Brockhaus F, Holzhauer B, Pethe A, Kay RA, et al. Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M,et Efficacyal. ofBI 671800, Kuna P, Bjermer L, Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et Prostaglandinal. D blind, placebo - - controlled clinical Clin trial. Exp Allergy. 2012;42(7):1097 controlled study of brodalumab, ahuman anti hinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory M, Metev H, Puu M, Richter K, Keen C, Uddin M, et al.Efficacy and safety ofa – - - dose inhaled corticosteroids. Eur Respir J. 2017;50(2). 707. blind, Placebo - , Zervas E, Alagha K,Hargreave FE, O’Byrne PM, et Safety andal. efficacy controlled trial. Lancet Respir Med. 2016;4(10):797 – st, in poorly controlled asthma as sole controller and in the presence of 1018.
Tornling G. Two Phase IIrandomized trials on the CRTh2 antagonist andin DP2 receptor (CRTh2) antagonist, in allergic asthma –
Curr Opin Pulm Med. 2019 12.
Respir Crit Care Med. 2013
- blind, parallel - controlled Study ofTumor Necrosis Factor rget in symptomatic corticosteroid dependent asthma. - ur CL. Induction of human airway alp - group, placebo ha. Eur Jha. Pharmacol. 1995 - IL ;25(1):121 - 17 receptor monoclonal antibody, i
;188(11):1294 - controlled – - 103. 127. – – – 44. 9. 70. –
558.
-
E, etal.A – –
806.
trial. Lancettrial. Respir 302.
;284(1 -
Blockade in
–
405. – 2):221 -
blind, – n 5. ₂
This article isprotected rights by All copyright. reserved. Accepted210. Eur Respir J Suppl. 2002;37:9s 209. for adults with asthma. Cochra 208. definitions and conceptual fram 207. complex, heterogeneous disease. Lancet. 2008 Sep;372(9643):1107 206. https://www.cancer.gov/publications/dictionaries/genetics 205. Asthma. Front Med. 2017;4:158. 204. results from two prospective multicentre studies. Eur Respir J. 2017;50(2). of bronchial thermoplasty in subjects with severe asthma: a comparison of 3 203. 2010 multicenter, randomized, double Effectiveness and safety of bronchial thermoplasty in the treatment ofsevere asthma: a 202. 2007 Articleof bronchial thermoplasty in symptomatic, severe asthma. Am J R 201. during the year after bronchial thermop 200. Med. 2018 ablation after bronchial thermoplasty and sustain 199. targeted treatments for severe uncontrolled asthma. Lancet Respir Med. 2016;4(7):585 198. 2017 asthma (AMAZES): a randomised, double azithromycin on asth 197. randomised double Azithromycin 196.
;181(2):116 ;176(12):1185 ;390(10095):659 van Bragt JJMH, Vijverberg SJH, Weersink EJM, Richards LB, Neerincx AH, Sterk PJ, et al. Pizzichini E,Pizzichini MMM, Leigh R,Dj Petsky HL, Kew KM, Turner C,Chang AB. Exhaled nitric oxide levels to guide treatment Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred Anderson GP. En NIH Svenningsen S, Nair P. A Chupp G, Laviolette M, Cohn L, Castro M,Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M,Sha Pavord ID,Co Cox G, Thomson RubinNC, AS, Niven RM, Corris PA, Siersted HC, et Asthmaal. control Facciolongo Di N, Stefano A, Pietrini Galeone V, C, Bellanova F, Menzella F, et Nerve al. Trivedi A, Pavord ID, Castro M.Bronchial thermoplasty and b Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge James S, AL, et al. Effect of Brusselle GG, Vanderstichele C,Jordens P, Deman R, Slabbynck H, Ringoet etV, al. ;18(1):29. - National Cancer Institute [Internet]. Available from: for prevention of exacerbations in severe asthma (AZISAST): a multicentre – 24. - – blind placebo
91. ma exacerbationsma and quality of life in adults with persistent uncontrolled x G, Thomson Rubin NC, AS, Corris PA, Niven RM, et al. Safety and efficacy
– 68. dotyping asthma: new insights into key pathogenic mechanisms in a
– ne Database Syst Rev. 2016 18s. sthma Endotypes and an Overview of Targeted Therapy for ework. Clin Pharmacol Ther. 2001;69(3):89 - blind, sham - controlled trial. Thorax. 2013;68(4):322
McEvoy C,Bansal S, Shifren A, et Longal. lasty. lasty. EnglN J Med. 2007 - blind, placebo - controlled clinical trial. Am J R ukanović R, Sterk PJ. Safety of sputum induction. ed improvement in se - controlled trial. Lanc ;9:CD011440.
- dictionary/def/phenotype ;356(13):1327 espir Crit Care Med. – iological therapy as 19. vere asthma. BMC Pulm
–
– 9. espir Crit Care Med. - 95. year follow h PL, et al. et Lond Engl.
- – term outcomes
37.
–
- 92. up
This article isprotected rights by All copyright. reserved. clinicalhead trials are required. proof on based arrow: Dashed hyperresponsiveness. ** and/orcontrol asthma quality oflife). (e.g. evaluation response clinical the of evaluation the to * asthma endotype and Figure 2.Figure laboratory) cost or patientoutcomes),(improvemanagement),‘Economical’(cost‘Valuable’ (changepatient which val a such outlines approach SAVED The met. be disease should criteria validation predict and subtypes disease However identify progression. disease, and health between discriminate markers identify to order in activitybiological of markers for screening are studies Several 1.Figure legendsFigure 2011;105(4):526 NO and exhaled breath condensate pH in the evaluation of asthma Respircontrol. Med. 211. Expert Rev Respir Med. 2018;12(5):361 Blood biomarkers in chronic airways diseases and their role in diagnosis a : Suggested biomarkersSuggested : Accepted therapy of evaluation For : Article
the following criteria are proposed: are criteriafollowing the Kostikas K,Papaioannou AI, Tanou K,Giouleka P, Koutsokera A, Minas M, et al. Exhaled 3. - fetv) n ‘lncly Deployable ‘Clinically and effective)
Clinical a Asthma endotypes and targeted treatment approaches. Practical
(14)
.
– 32. pplicability ofbiomarkers in asthma management. Adapted from
flow chart chart flow
applicable ,
to evaluate treatment response of targeted therapy are complementarytherapytargetedare treatmentresponse evaluate of to n re t casf a a clinical a as classify to order in -
of
biomarkers. options treatment targeted to - ocp suisfr hc adtoa pamtc o pragmatic additional which for studies concept - eitn ara osrcin n/r eee airway severe and/or obstruction airway resistant
– 74.
‘Superior’ (outperform current practice), ‘Actionable’practice),‘Superior’ current (outperform
(nlss ehooy vial i clinical in available technology (analysis ’
ly sha xcrain ae asthma rate, exacerbation asthma
plcbe biomarker applicable for
severe asthma severe nd management. dto poes in process idation according to according
(19) , head r
different . -
saving that - to -
This article isprotected rights by All copyright. reserved. Accepted Article and measured responses to atherapeutic intervention objectively (NIH definition) is that characteristic a pharmacologic or processes,pathogenic processes, biologic normal of indicator an as evaluated as defined is biomarker A Biomarker: functionally and pathologically by a molecular mechanism or by treatment response Endotype Endotype: Health (NIH) definition) Institute(Nationalparticularofgenotype a withindividualan presentationof clinical the genes; Phenotype: Box 1. Definitions h osral caatrsis n n niiul eutn fo te xrsin of expression the from resulting individual an in characteristics observable The
–
(205) cnrcin f endophenotype of contraction a .
(207)
–
. s sbye f ies defined disease of subtype a is
(206) .
This article isprotected rights by All copyright. reserved. induction Sputum brushings * lavage * * Bronchoscopy Table Bronchial Bronchial Broncho Biopsy Accepted Article method Sampling
1. (BAL)
Advantages and limitations of biomarker sampling methods inasthma -
alveolar alveolar
chemokines Cytokines, markers a Cell counts cell inflammatory Total Neutrophils Eosinophils
Biomarker remodelling Airway mediators markers and Leakage chemokines Cytokines counts cell inflammatory Total Neutrophils Eosinophils ctivation ctivation
, leakage leakage
and and
sputum eosinophils eosinophils sputum on based treatment adapting However, neutrophils sputum indicate ≥61% to eosinophil sputum indicate to used ≥3% are cut In general, lacking Clear cut Cut off level off Cut
- off values off values i a, and and a,
- off of of off
.
experienced centres experienced in monitoring and phenotyping disease for method Suitable of cel readout Reproducible biomarkers; read Semi direct Semi - l differentials l direct read direct Advantages .
- - out; multiple out; multiple out
disorders cardiovascular concomitant FEV lung function compromised with disease severe very for needed protocol Adapted 80 approx. in available samples Analysable Semi Dilution (BAL) bias site sampling Potential tissue variation address to needed sampling Multiple disorders cardiovascular with and/or function lung with compromised disease severe very in Not feasible complex Technically Invasive 1 - <1L invasive
(209) Limitations - 90% of subjects; 90% concomitant concomitant (contra
and/or with with and/or
- indicated if indicated
AcceptedThis article isprotected rights by All copyright. reserved. condensate breath Exhaled breath Exhaled Article blood Peripheral
compounds (VOCs) compounds organic Volatile FeNO mediators chemokines Cytokines, (total/specific) IgE markers Cell Eosinophils mediators markers Leukotrienes stress oxidative Markers of pH
Activation Activation
and and
and and
eosinophil cut eosinophil sputum various with performed has Study showed that that Study showed values. cut clear No years)(<12 >50 FeNO years), high <20 (<12 yrs), (≥12 25 ppb FeNO < Low guidelines: to clinical According eosinophils blood used for / 1 cells/µL ranging 150 mostly values, Various cut (208) 2 ranging from (≥12 yrs), <35 <35 yrs), (≥12
-
- - (210) - (58) off 4% are 4% are
off off 500 - offs, offs, - 8%
measurements Non Direct readout monitoring and phenotyping f method Suitable serial measurements repeatable, allowing method Simple Non to collect Easy - - invasive, allowing serial serial allowing invasive, invasive
or disease disease or
treatment during adequately not do eosinophils blood N.B:
issues to technical due outcomes Variable Expensive needed lab Specialized analysis and VOC collection for of methods standardized Lack FeNO levels affecting factors Various perturbing High readout Indirect Semi specialized routine clinical daily for variable too markers (soluble procedure consuming time and complex Technically
systemic corticosteroid systemic - intra invasive
(52) reflect airway reflect - assays subject diurnal diurnal subject
centres
) , restricted to to restricted ,
eosinophilia
variability
-
AcceptedThis article isprotected rights by All copyright. reserved. ArticlePET) 3He/129Xe) (hyperpolarized HRCT, qCT, (e.g. Imaging
MRI, MRI,
Airway remodeling Airway chemokines or Cytokines
well not of indicative was pH EBC ≤7.20 lacking cut Clear asthma - uncontrolled uncontrolled
(211) - off values values off
Enables to study structural (and (and aspects functional) structural study to Enables Non - invasive
Radiation exposure (e.g. qCT) (e.g. exposure Radiation is lacking Standardization validation and development further Awaits
This article isprotected rights by All copyright. reserved. Accepted Article
This article isprotected rights by All copyright. reserved. Accepted Article
This article isprotected rights by All copyright. reserved. Accepted Article